

ON P  
AUG 10 2000  
PATENT & TRADEMARK OFFICE

08-14-00

424 Rec'd PCT/PTO 10 AUG 2000

PCT

PCT/PTO-1500 (Rev. 10-20-99)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 256/153	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>09/622104</b>	
INTERNATIONAL APPLICATION NO. PCT/US99/02603		INTERNATIONAL FILING DATE 05-Feb-99		PRIORITY DATE CLAIMED 13-Feb-98	
TITLE OF INVENTION NOVEL MIXED AMYLIN ACTIVITY COMPOUNDS					
APPLICANT(S) FOR DO/EO/US BEELEY, Nigel; PRICKETT, Kathryn and BEAUMONT, Kevin					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11. to 16. below concern document(s) or information included:					
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: - Small Entity Status Statement - Copy of Notification of Receipt of Record Copy					

09/622104-071704

EL356077193US

U.S. APPLICATION NO. (If foreign, use 37 CFR 1.53) <b>09/622104</b>		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER																										
17. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$96.00  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>CALCULATIONS</b> PTO USE ONLY																										
				Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> <th style="width: 20%;"></th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>25</td> <td>- 20 =</td> <td>5</td> <td>X \$18.00</td> </tr> <tr> <td>Independent claims</td> <td>3</td> <td>- 3 =</td> <td>0</td> <td>X \$78.00</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$260.00</td> </tr> <tr> <td colspan="4"><b>TOTAL OF ABOVE CALCULATIONS =</b></td> <td>\$ 920</td> </tr> </tbody> </table> Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28). <b>SUBTOTAL =</b> \$ 460 Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). <b>TOTAL NATIONAL FEE =</b> \$ 460 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$ <b>TOTAL FEES ENCLOSED =</b> \$ 460 <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 80%;">Amount to be refunded:</td> <td style="width: 20%;">\$</td> </tr> <tr> <td>charged:</td> <td>\$ 460</td> </tr> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		Total claims	25	- 20 =	5	X \$18.00	Independent claims	3	- 3 =	0	X \$78.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$260.00	<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 920
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																											
Total claims	25	- 20 =	5	X \$18.00																										
Independent claims	3	- 3 =	0	X \$78.00																										
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$260.00																										
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 920																										
Amount to be refunded:	\$																													
charged:	\$ 460																													
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>12-2475</u> in the amount of \$ <u>460</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>12-2475</u> . A duplicate copy of this sheet is enclosed.																														
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.																														
SEND ALL CORRESPONDENCE TO:																														
SIGNATURE: <u>BERKMAN, Charles S.</u>																														
NAME: <u>38,077</u>																														
REGISTRATION NUMBER																														

Attorney's Docket No. 256/153

Applicant or Patentee: Amylin Pharmaceuticals, Inc.  
Serial or Patent No.: Not Yet Assigned  
Filed or Issued: Herewith  
For: Novel Mixed Amylin Activity Compounds

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) AND 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
- ☒ an official of the small business concern empowered to act on behalf of the concern identified below:

Name of Concern: Amylin Pharmaceuticals, Inc.  
Address of Concern: 9373 Towne Centre Drive  
San Diego, CA 92121

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-part or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled

Novel Mixed Amylin Activity Compounds

by inventor(s) Nigel R. Beelev; Kathryn S. Prickett; and Kevin Beaumont

described in

- ☒ the specification filed herewith
- ☐ the application serial no. \_\_\_\_\_, filed \_\_\_\_\_.
- ☐ patent no. \_\_\_\_\_, issued \_\_\_\_\_.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

Attorney's Docket No. 256/153

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ Individual

☐ Small Business Concern

☐ Nonprofit Organization

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ Individual

☐ Small Business Concern

☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small business entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING \_\_\_\_\_ Nancy K. Dahl, Esq.

TITLE OF PERSON SIGNING \_\_\_\_\_ Vice President and General Counsel

ADDRESS OF PERSON SIGNING \_\_\_\_\_ Amylin Pharmaceuticals, Inc.

9373 Towne Centre Drive

San Diego, CA 92121

SIGNATURE \_\_\_\_\_ N.K. Dahl DATE \_\_\_\_\_ 8-10-00

NOVEL MIXED AMYLIN ACTIVITY COMPOUNDSFIELD OF THE INVENTION

The present invention is directed to compounds which inhibit certain activities of amylin but which also act as amylin agonists with respect to other amylin activities. These compounds are useful in treating disturbances in fuel metabolism in mammals, including, but not limited to diabetes mellitus, including Type I diabetes and Type II diabetes, impaired glucose tolerance, insulin resistance and Syndrome X.

BACKGROUND AND INTRODUCTION TO THE INVENTION

Diabetes mellitus is a serious metabolic disease that is defined by the presence of chronically elevated levels of blood glucose (hyperglycemia). This state of hyperglycemia is the result of a relative or absolute lack of activity of the peptide hormone, insulin. Insulin is produced and secreted by the  $\beta$  cells of the pancreas. Insulin is reported to promote glucose utilization, protein synthesis, and the formation and storage of carbohydrate energy as glycogen. Glucose is stored in the body as glycogen, a form of polymerized glucose, which may be converted back into glucose to meet metabolism requirements. Under normal conditions, insulin is secreted at both a basal rate and at enhanced rates following glucose stimulation, all to maintain metabolic homeostasis by the conversion of glucose into glycogen.

The term diabetes mellitus encompasses several different hyperglycemic states. These states include Type I (insulin-dependent diabetes mellitus or IDDM) and Type II (non-insulin dependent diabetes mellitus or NIDDM) diabetes. The hyperglycemia present in individuals with Type I diabetes is associated with deficient, reduced, or nonexistent levels of insulin which are insufficient to maintain blood glucose levels within the physiological range. Treatment of Type I diabetes involves

administration of replacement doses of insulin, generally by a parenteral route. The hyperglycemia present in individuals with Type II diabetes is initially associated with normal or elevated levels of insulin; however, these individuals are unable to maintain metabolic homeostasis due to a state of insulin resistance in peripheral tissues and liver and, as the disease advances, due to a progressive deterioration of the pancreatic  $\beta$  cells which are responsible for the secretion of insulin. Thus, initial therapy of Type II diabetes may be based on diet and lifestyle changes augmented by therapy with oral hypoglycemic agents such as sulfonylureas. Insulin therapy is often required, however, especially in the latter states of the disease, in attempting to produce some control of hyperglycemia and minimize complications of the disease.

The structure and biology of amylin have previously been reviewed. See, for example, Young, Current Opinion in Endocrinology and Diabetes, 4:282-290 (1997); Gaeta and Rink, Med. Chem. Res., 3:483-490 (1994); and, Pittner et al., J. Cell. Biochem., 55S:19-28 (1994). Amylin is a 37 amino acid peptide hormone. It was isolated, purified and

chemically characterized as the major component of amyloid deposits in the islets of pancreases of deceased human Type II diabetics (Cooper et al., *Proc. Natl. Acad. Sci. USA*, 84:8628-8632 (1987)). The amylin molecule has two  
5 important post-translational modifications: the C-terminus is amidated, i.e., the 37th residue is tyrosinamide, and the cysteines in positions 2 and 7 are cross-linked to form an intra-molecular N-terminal loop, both of which are essential for full biologic activity (Cooper et al., *Proc.*  
10 *Natl. Acad. Sci. USA*, 85:7763-7766 (1988)). Amylin is the subject of United States Patent No. 5,367,052, issued November 22, 1994.

In Type I diabetes and late stage Type II diabetes, amylin has been shown to be deficient and combined  
15 replacement with insulin has been proposed as a preferred treatment over insulin alone in all forms of insulin-dependent diabetes. The use of amylin and amylin agonists for the treatment of diabetes mellitus is the subject of United States Patent No. 5,175,145, issued December 29,  
20 1992. Pharmaceutical compositions containing amylin and amylin plus insulin are described in United States Patent No. 5,124,314, issued June 23, 1992.

Excess amylin action has been said to mimic key features of the earlier stages of Type II diabetes and  
25 amylin blockade has been proposed as a novel therapeutic strategy. It has been disclosed in United States Patent No. 5,266,561, issued November 30, 1993, that amylin causes reduction in both basal and insulin-stimulated incorporation of labeled glucose into glycogen in skeletal  
30 muscle. The latter effect was also disclosed to be shared

by calcitonin gene related peptide (CGRP) (see also Leighton and Cooper, *Nature*, 335:632-635 (1988)). Amylin and CGRP were approximately equipotent, showing marked activity at 1 to 10 nM. Amylin is also reported to reduce insulin-stimulated uptake of glucose into skeletal muscle and reduce glycogen content (Young et al., *Amer. J. Physiol.*, 259:45746-1 (1990)). The treatment of Type II diabetes and insulin resistance with amylin antagonists is disclosed.

Amylin is primarily synthesized in pancreatic beta cells and is secreted in response to nutrient stimuli such as glucose and arginine. Studies with cloned beta-cell tumor lines (Moore et al., *Biochem. Biophys. Res. Commun.*, 179(1) (1991)) and perfused rat pancreases (Ogawa et al., *J. Clin. Invest.*, 85:973-976 (1990)) have shown that short pulses, 10 to 20 minutes, of nutrient secretagogues such as glucose and arginine, stimulate release of amylin as well as insulin. The molar amylin:insulin ratio of the secreted proteins varies between preparations from about 0.01 to 0.4, but appears not to vary much with acute stimuli in any one preparation. However, during prolonged stimulation by elevated glucose, the amylin:insulin ratio can progressively increase (Gedulin et al., *Biochem. Biophys. Res. Commun.*, 180(1):782-789 (1991)). Thus, amylin and insulin are not always secreted in a constant ratio.

It has been discovered and reported that certain actions of amylin are similar to non-metabolic actions of CGRP and calcitonin; however, the metabolic actions of amylin discovered during investigations of this recently identified protein appear to reflect its primary biologic



role. At least some of these metabolic actions are mimicked by CGRP, albeit at doses which are markedly vasodilatory (see, e.g., Leighton and Cooper, *Nature*, 335:632-635 (1988)); Molina et al., *Diabetes*, 39:260-265 (1990)).

The first discovered action of amylin was the reduction of insulin-stimulated incorporation of glucose into glycogen in rat skeletal muscle (Leighton and Cooper, *Nature*, 335:632-635 (1988)); the muscle, thus, became "insulin-resistant". Subsequent work with rat soleus muscle *ex-vivo* and *in vitro* has indicated that amylin reduces glycogen synthase activity, promotes conversion of glycogen phosphorylase from the inactive b form to the active a form, promotes net loss of glycogen (in the presence or absence of insulin), increases glucose-6-phosphate levels, and can increase lactate output (see, e.g., International Patent Application No. PCT/US92/00185, published July 23, 1992 (International Publication No. WO 92/11863). Amylin appears not to affect glucose transport per se (e.g., Pittner et al., *FEBS Letts.*, 365(1):98-100 (1995)). Studies of amylin and insulin dose-response relations show that amylin acts as a noncompetitive or functional antagonist of insulin in skeletal muscle (Young et al., *Am. J. Physiol.*, 263(2):E274-E281 (1992)). There is no evidence that amylin interferes with insulin binding to its receptors, or the subsequent activation of insulin receptor tyrosine kinase (Follett et al., *Clinical Research*, 39(1):39A (1991)); Koopmans et al., *Diabetologia*, 34:218-224 (1991)).

It is believed that amylin acts through receptors

present in plasma membranes. Studies of amylin and CGRP, and the effect of selective antagonists, have led to reports that amylin acts via its own receptor (Beaumont et al., *Br. J. Pharmacol.*, 115(5):713-715 (1995); Wang et al., *FEBS Letts.*, 219:195-198 (1991 b)), in contrast to the conclusion of other workers that amylin may act primarily at CGRP receptors (e.g., Chantry et al., *Biochem. J.*, 277:139-143 (1991)); Zhu et al., *Biochem. Biophys. Res. Commun.*, 177(2):771-776 (1991)). Amylin receptors and their use in methods for screening and assaying for amylin agonist and antagonist compounds are described in United States Patent No. 5,264,372, issued November 23, 1993.

While amylin has marked effects on hepatic fuel metabolism *in vivo*, there is no general agreement as to what amylin actions are seen in isolated hepatocytes or perfused liver. The available data do not support the idea that amylin promotes hepatic glycogenolysis, i.e., it does not act like glucagon (e.g., Stephens et al., *Diabetes*, 40:395-400 (1991); Gomez-Foix et al., *Biochem J.*, 276:607-610 (1991)). It has been suggested that amylin may act on the liver to promote conversion of lactate to glycogen and to enhance the amount of glucose able to be liberated by glucagon. In this way, amylin could act as an anabolic partner to insulin in liver, in contrast to its catabolic action in muscle.

In fat cells, contrary to its action in muscle, amylin has no detectable actions on insulin-stimulated glucose uptake, incorporation of glucose into triglyceride, CO<sub>2</sub> production (Cooper et al., *Proc. Natl. Acad. Sci.*, 85:7763-7766 (1988)) epinephrine-stimulated lipolysis, or insulin-

inhibition of lipolysis (Lupien and Young, "Diabetes Nutrition and Metabolism - Clinical and Experimental," Vol. 6(1), pages 1318 (February 1993)). Amylin thus exerts tissue-specific effects, with direct action on skeletal muscle, marked indirect (via supply of substrate) and perhaps direct effects on liver, while adipocytes appear "blind" to the presence or absence of amylin.

It has also been reported that amylin can have marked effects on secretion of insulin. In the perfused pancreas (Silvestre *et al.*, *Reg. Pept.*, 31:23-31 (1990)), and in the intact rat (Young *et al.*, *Mol. Cell. Endocrinol.*, 84:R1-R5 (1992)), some experiments indicate that amylin inhibits insulin secretion. Other workers, however, have been unable to detect effects of amylin on isolated  $\beta$ -cells, on isolated islets, or in the whole animal (see Broderick *et al.*, *Biochem. Biophys. Res. Commun.*, 177:932-938 (1991) and references therein).

Amylin and amylin agonists have also been shown to suppress glucagon secretion. When influences that would otherwise affect glucagon secretion were controlled (plasma glucose, insulin and blood pressure), amylin reportedly suppressed the glucagon response to arginine in rats. Gedulin *et al.*, *Metabolism*, 46:67-70 (1997). The amylin analogue, pramlintide, has been reported to eliminate the post-prandial surge in glucagon concentration in subjects with Type I diabetes. Fineman *et al.*, *Diabetes*, 40:30A (1997). Pramlintide, and other amylin agonist analogues, are described and claimed in U.S. Patent No. 5,686,411, issued November 11, 1997. A glucagonostatic effect of amylin has not been demonstrated in the isolated perfused

pancreas (Silvestre et al., *Regul. Pept.*, 31:23-31 (1990), indicating that amylin may exert its glucagonostatic action via an extrapancreatic mechanism. The observation that suppression of glucagon secretion does not occur with the amylin analogue, pramlintide, in humans during insulin-induced hypoglycemia (Nyholm et al., *J. Clin. Endocrin. Metab.*, 81:1083-1089 (1996); Kolterman et al., *Diabetologia*, 39:492-499 (1996)) further supports the idea that this effect is not directly on  $\alpha$  cells but could be centrally mediated.

Amylin and amylin agonists potently inhibit gastric emptying in rats (Young et al., *Diabetologia* 38(6):642-648 (1995)), dogs (Brown et al., *Diabetes* 43(Suppl 1):172A (1994)) and humans (Macdonald et al., *Diabetologia* 38(Suppl 1):A32 (abstract 118) (1995)). Gastric emptying is reportedly accelerated in amylin-deficient Type I diabetic BB rats (Young et al., *Diabetologia*, *supra*; Nowak et al., *J. Lab. Clin. Med.*, 123(1):110-6 (1994)) and in rats treated with the amylin antagonist, AC187 (Gedulin et al., *Diabetologia*, 38(Suppl 1):A244 (1995)). The effect of amylin on gastric emptying appears to be physiological (operative at concentrations that normally circulate).

Non-metabolic actions of amylin include vasodilator effects which may be mediated by interaction with CGRP vascular receptors. Reported *in vivo* tests suggest that amylin is at least about 100 to 1000 times less potent than CGRP as a vasodilator (Brain et al., *Eur. J. Pharmacol.*, 183:2221 (1990); Wang et al., *FEBS Letts.*, 291:195-198 (1991)).

Injected into the brain, or administered peripherally,

amylin has been reported to suppress food intake, *e.g.*, Chance *et al.*, *Brain Res.*, 539:352-354 (1991)), an action shared with CGRP and calcitonin. The effective concentrations at the cells that mediate this action are not known. Amylin has also been reported to have effects both on isolated osteoclasts where it caused cell quiescence, and *in vivo* where it was reported to lower plasma calcium by up to 20% in rats, in rabbits, and in humans with Paget's disease (*see, e.g.*, Zaidi *et al.*, *Trends in Endocrinal. and Metab.*, 4:255-259 (1993)). From the available data, amylin seems to be 10 to 30 times less potent than human calcitonin for these actions. Interestingly, it was reported that amylin appeared to increase osteoclast cAMP production but not to increase cytosolic  $Ca^{2+}$ , while calcitonin does both (Alam *et al.*, *Biochem. Biophys. Res. Commun.*, 179(1):134-139 (1991)). It was suggested, though not established, that amylin may act via a single receptor type whereas calcitonin may act via two receptors, one of which is common to amylin activity.

It has also been discovered that, surprisingly in view of its previously described renal vasodilator and other properties, amylin markedly increases plasma renin activity in intact rats when given subcutaneously in a manner that avoids any disturbance of blood pressure. This latter point is important because lowered blood pressure is a strong stimulus to renin release. Amylin antagonists, such as amylin receptor antagonists, including those selective for amylin receptors compared to CGRP and/or calcitonin receptors, can be used to block the amylin-evoked rise of plasma renin activity. The use of amylin antagonists to

treat renin-related disorders is described in United States Patent No. 5,376,638, issued December 27, 1994.

In normal humans, fasting amylin levels from 1 to 10 pM and post-prandial or post-glucose levels of 5 to 20 pM have been reported (see, e.g., Koda et al., *The Lancet*, 339:1179-1180 (1992)). In obese, insulin-resistant individuals, post-food amylin levels can go higher, reaching up to about 50pM. For comparison, the values for fasting and post-prandial insulin are 20 to 50pM, and 100 to 300 pM respectively in healthy people, with perhaps 3-to 4-fold higher levels in insulin-resistant people. In Type I diabetes, where beta cells are destroyed, amylin levels are at or below the levels of detection and do not rise in response to glucose (Koda et al., *The Lancet*, 339:1179-1180 (1992)). In normal mice and rats, basal amylin levels have been reported from 30 to 100 pM, while values up to 600 pM have been measured in certain insulin-resistant, diabetic strains of rodents (e.g., Huang et al., *Hypertension*, 19:I-101-I-109 (1991)).

In mammals, calcitonin functions in the regulation of bone marrow turnover and calcium metabolism. Calcitonin, which is caused to be released from the thyroid by elevated serum calcium levels, produces actions on bone and other organs which tend to reduce serum calcium levels.

Calcitonin inhibits osteoclast activity and reduces bone resorption, thereby reducing serum calcium levels. Calcitonin also alters calcium, phosphate and electrolyte excretion by the kidney, although the physiological significance of this is not reported. Calcitonin has been used clinically for treatment of disorders of calcium

metabolism and pain, and its relationship to increased glucose levels in mammals has been the subject of varying reports. See, e.g., Azria et al., "Calcitonins -- Physiological and Pharmacological Aspects," pp. 24-25 (Springer-Verlag 1989). The use of calcitonins in the treatment of diabetes mellitus is described in United States Patent No. 5,321,008 issued June 14, 1994 and United States Patent No. 5,508,260 issued April 16, 1996.

Certain compounds reported to be calcitonin derivatives have been said to lower the calcium plasma level and to influence bone metabolism (United States Patent No. 4,758,550 to Cardinaux et al.).

#### SUMMARY OF THE INVENTION

The present invention provides novel compounds having activity in regulating the metabolic effects mediated by amylin in mammals. Surprisingly, these compounds inhibit certain effects of amylin and also act as amylin agonists for other of amylin's effects.

Among other factors, the present invention is based on our unexpected findings that the compounds of the present invention exhibit a biological profile of mixed amylin antagonism and agonism coupled with relatively weak binding at CGRP receptors. In particular, these compounds have been determined to act as amylin antagonists in blocking the glycogen-related responses associated with amylin action in muscle and also to act as amylin agonists in inhibiting of gastric emptying. It is believed that due to this surprising combination of biological effects, these compounds will be useful in treating diabetes, indicating

Type I diabetes, due to their effects on inhibition of gastric emptying, and will also be useful in treating impaired glucose tolerance, insulin resistance, Type II diabetes, particularly early Type II diabetes, and Syndrome

5 X due to their effects on glucose metabolism.

Additionally, due to their action on plasma calcium levels, the present compounds may be particularly advantageous.

The compounds of the present invention are also useful in performing studies relating to receptor

10 characterization, for example, characterization of receptors at which amylin bind. Additionally, the present compounds are useful as test compounds and control samples in the assays described in the Examples below.

According to the present invention, provided are  
15 compounds of the formula:

$X_1-X_2-X_3-Leu-X_4-Glu-Leu-X_5-X_6-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-X_7-Z_3$  [SEQ.ID.NO.27]

wherein

- (a)  $X_1$  is (i) a group having two amino acid residues  
20 selected from the group consisting of Leu-Leu, Val-Leu, Ile-Leu, tert-Leu-Leu, Nle-Leu, and Ala-Thr, and N-acylated derivatives thereof; or  
is (ii) the group  $Z_1-Ser-Thr-Z_2-Val-Leu$  [SEQ.ID.NO. 28] wherein  $Z_1$  is an amino acid residue selected from  
25 the group consisting of Leu, Val, Ile, tert-Leu, Nva, Abu, and Nle or an N-acylated derivative thereof or  $Z_1$  is an alkanoyl group; and  $Z_2$  is an amino acid residue selected from the group consisting of Ala, Ser, Cys, and Thr;
- 30 (b)  $X_2$  is an amino acid residue selected from the group



consisting of Gly, Glu, Asn or Aib;

- (c)  $X_3$  is an amino acid residue selected from the group consisting of Arg, Orn, Lys and  $\epsilon$ -amidated derivatives thereof;
- 5 (d)  $X_4$  is a group having two amino acid residues selected from the group consisting of Ser-Gln, Thr-Gln, Ala-Asn and Thr-Asn;
- (e)  $X_5$  is an amino acid residue selected from the group consisting of His, Aib, Ile, Leu and Val;
- 10 (f)  $X_6$  is an amino acid residue selected from the group consisting of Arg, Orn and Lys and  $\epsilon$ -amidated derivatives thereof;
- (g)  $X_7$  is a group having six amino acid residues selected from the group consisting of
- 15 (i) Thr-Gly-Ser-Asn-Thr-Tyr-NH<sub>2</sub> [SEQ.ID.NO. 29];  
(ii) Thr-Gly-Ser-Gly-Thr-Pro-NH<sub>2</sub> [SEQ.ID.NO. 30];  
(iii) Val-Gly-Ser-Asn-Thr-Tyr-NH<sub>2</sub> [SEQ.ID.NO. 31];  
(iv) Val-Gly-Ser-Gly-Thr-Pro-NH<sub>2</sub> [SEQ.ID.NO. 32]; and
- (h)  $Z_1$  is OH or NH<sub>2</sub>;
- 20 with the proviso that the compound does not have the formula of any of SEQ. ID. Nos. 14 to 26;  
and pharmaceutically acceptable salts thereof.

### Definitions

- In accordance with the present invention and as used
- 25 herein, the following terms are defined to have the following meanings, unless explicitly stated otherwise.

The term "amylin" is understood to include the human peptide hormone amylin secreted from the beta cells of the pancreas.

"Amylin agonist" is also a term known in the art, and refers to a compound which has biological activities of amylin. An amylin agonist may be a peptide or a non-peptide compound. Such compounds may act as amylin agonists, normally, it is presently believed, by virtue of binding to or otherwise directly or indirectly interacting with an amylin receptor or other receptor or receptors with which amylin itself may interact to elicit a biological response.

The term "amylin antagonist" refers to a compound which inhibits effects of amylin. An amylin antagonist may be a peptide or a non-peptide compound.

The term "alkanoyl" refers to the group  $RC(=O)-$  wherein R is a straight chain or branched chain alkyl group, which may be derived from a corresponding carboxylic acid.

The term "amino acid" refers to natural amino acids, unnatural amino acids, and amino acid analogs, all in their D and L stereoisomers if their structure allow such

stereoisomeric forms. Natural amino acids include alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), Lysine (Lys), methionine (Met),


phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), typtophan (Trp), tyrosine (Tyr) and valine (Val).

Unnatural amino acids include, but are not limited to azetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, aminopropionic acid, 2-aminobutyric acid (Abu), 4-aminobutyric acid, 6-aminocaproic acid, 2-

aminoheptanoic acid, 2-aminoisobutyric acid (Aib), 3-aminoisobutyric acid, 2-aminopimelic acid, tertiary-butylglycine, 2,4-diaminoisobutyric acid, desmosine, 2,2'-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, homoproline, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylalanine, N-methylglycine, N-methylisoleucine, N-methylpentylglycine, N-methylvaline, naphthalanine, norvaline (Nva), norleucine (Nle), ornithine (Orn), pentylglycine, pipecolic acid and thioproline. Amino acid analogs include the natural and unnatural amino acids which are chemically blocked, reversibly or irreversibly, or modified on their N-terminal amino group or their side-chain groups, as for example, methionine sulfoxide, methionine sulfone, S-(carboxymethyl)-cysteine, S-(carboxymethyl)-cysteine sulfoxide and S-(carboxymethyl)-cysteine sulfone.

The term "amino acid analog" refers to an amino acid wherein either the C-terminal carboxy group, the N-terminal amino group or side-chain functional group has been chemically codified to another functional group. For example, aspartic acid-(beta-methyl ester) is an amino acid analog of aspartic acid; N-ethylglycine is an amino acid analog of glycine; or alanine carboxamide is an amino acid analog of alanine.

The term "amino acid residue" refers to radicals having the structure: (1)  $-C(O)-R-NH-$ , wherein R typically is  $-CH(R')$ , wherein R' is an amino acid side chain, typically H or a carbon containing substituent; or (2)



wherein p is 1, 2 or 3 representing the azetidinecarboxylic acid, proline or pipercolic acid residues, respectively.

5 The term "lower" referred to herein in connection with organic radicals such as alkyl groups defines such groups with up to and including about 6, preferably up to and including 4 and advantageously one or two carbon atoms. Such groups may be straight chain or branched chain.

10 "Pharmaceutically acceptable salt" includes salts of the compounds of the present invention derived from the combination of such compounds and an organic or inorganic acid. In practice the use of the salt form amounts to use of the base form. The compounds of the present invention  
15 are useful in both free base and salt form, with both forms being considered as being within the scope of the present invention.

In addition, the following abbreviations stand for the following:

20 "Ac" refers to acetyl.

"ACN" or "CH<sub>3</sub>CN" refers to acetonitrile.

"Boc", "tBoc" or "Tboc" refers to t-butoxy carbonyl.

"DCC" refers to N,N'-dicyclohexylcarbodiimide.

"Fmoc" refers to fluorenylmethoxycarbonyl.

"For" refers to formamidated, for example, "Lys(For)" refers to formamidated lysine.

"HBTU" refers to 2-(1H-benzotriazol-1-yl)-

5 1,1,3,3,-tetramethyluronium hexafluorophosphate.

"HOBt" refers to 1-hydroxybenzotriazole monohydrate.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts calcitonin receptor-coupled stimulation of adenylyl cyclase by the compound of Example 1 ("Compound 1") [SEQ.ID.NO. 1]. Cyclic AMP accumulation in T47D cells was measured as a function of test compound concentration.

Figures 2A and 2B depict *in vitro* amylin antagonist activity of Compound 1 (Figure 2A) and the compound of Example 2 ("Compound 2") [SEQ.ID.NO. 2] (Figure 2B) in the soleus muscle assay.

Figure 3 depicts a dose response curve for amylin antagonist activity of Compound 1 measured in the soleus muscle assay. Reversal of the effects of rat amylin on insulin-stimulated incorporation of <sup>14</sup>C-glucose in isolated soleus muscle at varying doses of test compound is shown.

Figures 4A to 4C depict the *in vivo* activity of Compound 1 on plasma glucose levels (Figure 4A), plasma lactate levels (Figure 4B) and plasma calcium levels (Figure 4C) in anesthetized rats.

Figures 5A to 5C depict the *in vivo* activity of Compound 2 on plasma glucose levels (Figure 5A), plasma lactate levels (Figure 5B) and plasma calcium levels (Figure 5C) in anesthetized rats.

Figures 6A to 6C depict in vivo activity of Compound 1 and Compound 2 in inhibiting effects of rat amylin on plasma levels of glucose (Figure 6A), lactate (Figure 5B) and calcium (Figure 6C) in anesthetized rats. Also measured was mean arterial pressure (Figure 6D).

Figure 7 depicts a dose response curve for the in vivo effects of Compound 1 and Compound 2 on inhibition of gastric emptying in rats.


Figure 8 depicts the amino acid sequences of Compounds 1 to 13 [SEQ.ID.NOS. 1 to 13].

Figure 9 depicts the amino acid sequences of certain peptide compounds reported in the literature [SEQ.ID.NOS. 14 to 26]. The references for the sequences are as follows: SEQ.ID.NO. 14: 4-32 salmon calcitonin; SEQ.ID.NO. 15: 8-32 salmon calcitonin; SEQ.ID.NOS. 16 and 17: United States Patent No. 5,580,953; SEQ.ID.NOS. 18 and 19: Gamse et al., J. Bone Min. Res. 8 (Suppl 1): S200, Abstract #334 (1993); and SEQ.ID.NOS. 20 to 26: United States Patent No. 4,758,550.

## DETAILED DESCRIPTION OF THE INVENTION

### Preferred Compounds

According to the present invention, provided are compounds of formula:



wherein

- (a)  $X_1$  is (i) a group having two amino acid residues selected from the group consisting of Leu-Leu, Val-Leu, Ile-Leu, tert-Leu-Leu, Nle-Leu, and Ala-Thr, and

N-acylated derivatives thereof; or

(ii) the group  $Z_1$ -Ser-Thr- $Z_2$ -Val-Leu [SEQ.ID.NO.28] wherein  $Z_1$  is an amino acid residue selected from the group consisting of Leu, Val, Ile, tert-Leu, Nva, Abu, and Nle or N-acylated derivatives thereof or  $Z_1$  is an alkanyl group; and  $Z_2$  is a amino acid residue selected from the group consisting of Ala, Ser, Cys, and Thr;

- (b)  $X_2$  is an amino acid residue selected from the group consisting of Gly, Glu, Asn and Aib;
- (c)  $X_3$  is an amino acid residue selected from the group consisting of Arg, Orn, Lys and  $\epsilon$ -amidated derivatives thereof;
- (d)  $X_4$  is a group having two amino acid residues selected from the group consisting of Ser-Gln, Thr-Gln, Ala-Asn and Thr-Asn;
- (e)  $X_5$  is an amino acid residue selected from the group consisting of His, Aib, Ile, Leu and Val;
- (f)  $X_6$  is an amino acid residue selected from the group consisting of Arg, Orn and Lys and  $\epsilon$ -amidated derivatives thereof; and
- (g)  $X_7$  is a group having 6 amino acid residues selected from the group consisting of
- (i) Thr-Gly-Ser-Asn-Thr-Tyr-NH<sub>2</sub> [SEQ.ID.NO. 29];
  - (ii) Thr-Gly-Ser-Gly-Thr-Pro-NH<sub>2</sub> [SEQ.ID.NO. 30];
  - (iii) Val-Gly-Ser-Asn-Thr-Tyr-NH<sub>2</sub> [SEQ.ID.NO. 31];
  - (iv) Val-Gly-Ser-Gly-Thr-Pro-NH<sub>2</sub> [SEQ.ID.NO. 32]; and
- (h)  $Z_3$  is OH or NH<sub>2</sub>

with the proviso that the compound does not have the formula of any of SEQ. ID. NOS. 14 to 26. Also included within the scope of the present invention are

pharmaceutically acceptable salts of these compounds.

Preferred  $X_1$  groups include  $Z_1$ -Ser-Thr- $Z_2$ -Val-Leu.

Preferably  $Z_1$  is an alkanoyl group to give an N-terminal amidation derivative of serine with a carboxylic acid or

5 Leu. Suitable carboxylic acids include straight chain or branched chain carboxylic acids of 1 to about 10 carbon atoms, more preferably of about 6 to about 8 carbon atoms.

More preferably  $Z_1$  is an alkanoyl group to give an N-

terminal amidation. Especially preferred  $Z_1$  groups include

10 4-methylpentanoyl. Preferred  $Z_2$  groups include Ala or Cys, more preferably Ala.

Preferred  $X_2$  groups include Gly.

Preferred  $X_3$  groups include  $\epsilon$ -amidated derivatives which are amidated with a carboxylic acid having 1 to 8

15 carbon atoms. Preferably  $X_3$  is Lys  $\epsilon$ -amidated with formic or acetic acid. Especially preferred  $X_3$  groups include Lys(For).

Preferred  $X_4$  groups include Ser-Glu.

Preferred  $X_5$  groups include His or Aib. More

20 preferably  $X_5$  is Aib.

Preferred  $X_6$  groups include  $\epsilon$ -amidated derivatives

which are amidated with a carboxylic acid having 1 to 8

carbon atoms. Preferably  $X_6$  is Lys  $\epsilon$ -amidated with formic or acetic acid. Especially preferred  $X_6$  groups include

25 Lys(For).

Preferred  $X_7$  groups include Thr-Gly-Ser-Asn-Thr-Tyr-  
 $NH_2$  [SEQ.ID.NO. 29] and Thr-Gly-Ser-Gly-Thr-Pro- $NH_2$   
[SEQ.ID.NO. 30].

Preferably  $Z_3$  is  $NH_2$ .

30 According to an especially preferred aspect provided



are compounds wherein  $X_2$  is Gly,  $X_3$  is His or Aib,  $X_4$  is Ser-Glu,  $X_7$  is Thr-Gly-Ser-Asn-Thr-Tyr-NH<sub>2</sub> [SEQ.ID.NO. 29] or Thr-Gly-Ser-Gly-Thr-Pro-NH<sub>2</sub> [SEQ.ID.NO. 30],  $X_1$  is  $Z_1$  Ser-Thr- $Z_2$ -Val-Leu, where preferably  $Z_1$  is Leu or an alkanoyl group to give N-terminal amidation of serine with a carboxylic acid and  $Z_2$  is Ala or Cys;  $X_3$  and  $X_6$  are e-amidated with a carboxylic acid. For  $Z_1$ , preferred are carboxylic acids having 1 to about 10 carbon atoms, more preferably about 6 to about 8 carbon atoms. Especially preferred carboxylic acids include 4-methylpentanoic acid. More preferably  $Z_1$  is an alkanoyl group to give an N-terminal amidation. More preferably  $X_3$  and  $X_6$  are Lys amidated with formic or acetic acid. Especially preferred  $X_3$  and  $X_6$  groups include Lys(For).

Preferred peptide compounds of the present invention include those having amino acid sequences of SEQ.ID.NOS. 1 to 13 ("Compounds 1 to 13," respectively). Especially preferred peptide compounds include Compounds 1 and 2.

#### Amylin-Related Activity

Activities of the compounds of the present invention can be confirmed and quantified by performing various screening assays, including the receptor binding assays described below in Example A, the adenylyl cyclase stimulation assay described below in Example B, the soleus muscle assay described below in Example C, the measurement of plasma glucose, lactate and calcium levels as described below in Examples D and E, and the gastric emptying assay described below in Example F.

The nucleus accumbens receptor binding assay, a

competition assay which measures the ability of compounds to bind specifically to membrane-bound amylin receptors, is described in United States Patent No. 5,264,372, issued November 23, 1993, the disclosure of which is incorporated herein by reference. The nucleus accumbens receptor binding assay is also described in Example A below. A preferred source of the membrane preparations used in the assay is the basal forebrain which comprises membranes from the nucleus accumbens and surrounding regions. Compounds being assayed compete for binding to these receptor preparations with  $^{125}\text{I}$  Bolton Hunter rat amylin. Competition curves, wherein the amount bound (B) is plotted as a function of the log of the concentration of ligand are analyzed by computer, using analyses by nonlinear regression to a 4-parameter logistic equation (Inplot program; GraphPAD Software, San Diego, California) or the ALLFIT program of DeLean *et al.* (ALLFIT, Version 2.7 (NIH, Bethesda, MD 20892)). Munson and Rodbard, *Anal. Biochem.* 107:220-239 (1980).

The SK-N-MC cell binding assay, which measures the ability of compounds to bind specifically to CGRP receptors, is described in Example A below. The preferred source of the membrane preparations used in the assay are SK-N-MC human neuroblastoma cells which have been shown to contain a high-affinity CGRP receptor that is coupled to adenylyl cyclase and which has binding and specificity characteristics similar to CGRP receptors present in several other tissues (VanValen *et al.*, *Neuroscience Letters* 119:195-198, (1990).

The T47D cell binding assay which measures the ability

of compounds to bind specifically to calcitonin receptors, is described in Example A below. Membranes are prepared from T47D breast carcinoma cell cultures. Binding to calcitonin receptors is quantified by displacement of labeled salmon calcitonin.

Functional activity of compounds at calcitonin receptors can be measured according to the adenylyl cyclase assay described in Example B below. Human T47D and MCF7 breast carcinoma cells contain calcitonin receptors coupled to the stimulation of adenylyl cyclase activity. In these cells, calcitonin stimulates increases in cyclic AMP accumulation.

Assays of biological activity of compounds in the soleus muscle may be performed using previously described methods (Leighton, B. and Cooper, *Nature*, 335:632-635 (1988); Cooper, *et al.*, *Proc. Natl. Acad. Sci. USA* 85:7763-7766 (1988)), in which amylin agonist activity may be assessed by measuring the inhibition of insulin-stimulated glycogen synthesis. The soleus muscle assay is also described in Example C below.

Methods of measuring effects of compounds on plasma glucose, lactate and calcium levels are described in Examples D and E.

Methods of measuring the rate of gastric emptying are disclosed in, for example, Young *et al.*, *Diabetologia*, 38(6):642-648 (1995). In a phenol red method, which is described in Example F below, conscious rats receive by gavage an a caloric gel containing methyl cellulose and a phenol red indicator. Twenty minutes after gavage, animals are anesthetized using halothane, the stomach exposed and

clamped at the pyloric and lower esophageal sphincters, removed and opened into an alkaline solution. Stomach content may be derived from the intensity of the phenol red in the alkaline solution, measured by absorbance at a wavelength of 560 nm. In a tritiated glucose method, conscious rats are gavaged with tritiated glucose in water. The rats are gently restrained by the tail, the tip of which is anesthetized using lidocaine. Tritium in the plasma separated from tail blood is collected at various timepoints and detected in a beta counter. Test compounds are normally administered about one minute before gavage.

Preferably, compounds of the present invention exhibit activity in the nucleus accumbens receptor binding assay on the order of less than about 1 to 5 nM, and more preferably less than about 1 nM. In the soleus muscle assay these compounds preferably inhibit the effects of amylin in the concentration range of 1-100 nM, and more preferably in the range of 5-50 nM, and show  $IC_{50}$  values on the order of less than about 1 to 2  $\mu$ M. In the gastric emptying assays, preferred compounds show  $ED_{50}$  values on the order of less than 100  $\mu$ g/rat, and more preferably less than 10  $\mu$ g/rat.

#### Preparation of Compounds

The compounds of the present invention may be prepared using standard solid-phase peptide synthesis techniques and preferably an automated or semiautomated peptide synthesizer. Typically, using such techniques, an  $\alpha$ -N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin are coupled at room temperature in an inert solvent such as dimethylformamide,

N-methylpyrrolidinone or methylene chloride in the presence of coupling agents such as dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine. The  $\alpha$ -N-carbamoyl protecting group is removed from the resulting peptide-resin using a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid to be added to the peptide chain. Suitable N-protecting groups are well known in the art, with t-butyloxycarbonyl (tBoc) and fluorenylmethoxycarbonyl (Fmoc) being preferred herein. A preferred resin for use with Fmoc chemistry which delivers a c-terminal amide is a Rink Amide MBHA resin (4-(2',2'-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucyl-MBHA resin).

The solvents, amino acid derivatives and 4-methylbenzhydryl-amine resin used in the peptide synthesizer may be purchased from Applied Biosystems Inc. (Foster City, CA). Rink amide MBHA resin is available from Novabiochem (La Jolla, CA). The following side-chain protected amino acids may be purchased from Applied Biosystems, Inc.: Boc-Arg(Mts), Fmoc-Arg(Pmc), Boc-Thr(Bzl), Fmoc-Thr(t-Bu), Boc-Ser(Bzl), Fmoc-Ser(t-Bu), Boc-Tyr(BrZ), Fmoc-Tyr(t-Bu), Boc-Lys(Cl-Z), Fmoc-Lys(Boc), Boc-Glu(Bzl), Fmoc-Glu(t-Bu), Fmoc-His(Trt), Fmoc-Asn(Trt), and Fmoc-Gln(Trt). Boc-His(BOM) may be purchased from Applied Biosystems, Inc. or Bachem Inc. (Torrance, CA). Fmoc-Lys(For) and Fmoc-Aib may be purchased from Bachem, Inc. (Torrance, CA). Anisole, acetic anhydride, isocaproic acid, dimethylsulfide, phenol, ethanedithiol, and thioanisole may be obtained from Aldrich Chemical Company

(Milwaukee, WI). Air Products and Chemicals (Allentown, PA) supplies HF. Ethyl ether, acetic acid and methanol may be purchased from Fisher Scientific (Pittsburgh, PA).

Solid phase peptide synthesis may be carried out with an automatic peptide synthesizer (Model 430A, Applied Biosystems Inc., Foster City, CA) using the NMP/HOBt system and tBoc or Fmoc chemistry (see, Applied Biosystems User's Manual for the ABI 430A Peptide Synthesizer, Version 1.3B July 1, 1988, section 6, pp. 49-70, Applied Biosystems, Inc., Foster City, CA) with capping. Boc-peptide-resins may be cleaved with HF (-5°C to 0°C, 1 hour). The peptide may be extracted from the resin with alternating water and acetic acid, and the filtrates lyophilized. The Fmoc-peptide resins may be cleaved according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12). Peptides may also be assembled using an Advanced Chem Tech Synthesizer (Model MPS 350, Louisville, Kentucky).

Peptides may be purified by RP-HPLC (preparative and analytical) using a Waters Delta Prep 3000 system. A C<sub>4</sub>, C<sub>8</sub> or C<sub>18</sub> preparative column (10  $\mu$ , 2.2 x 25 cm; Vydac, Hesperia, CA) may be used to isolate peptides, and purity may be determined using a C<sub>4</sub>, C<sub>8</sub> or C<sub>18</sub> analytical column (5  $\mu$ , 0.46 x 25 cm; Vydac). Solvents (A=0.1% TFA/water and B=0.1% TFA/CH<sub>3</sub>CN) may be delivered to the analytical column at a flowrate of 1.0 ml/min and to the preparative column at 15 ml/min. Amino acid analyses may be performed on the Waters Pico Tag system and processed using the Maxima program. Peptides may be hydrolyzed by vapor-phase acid hydrolysis (115°C, 20-24 h). Hydrolysates may be

derivatized and analyzed by standard methods (Cohen, et al., The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation, Milford, MA (1989)). Fast atom bombardment analysis may be carried out by M-Scan, Incorporated (West Chester, PA). Mass calibration may be performed using cesium iodide or cesium iodide/glycerol. Plasma desorption ionization analysis using time of flight detection may be carried out on an Applied Biosystems Bio-Ion 20 mass spectrometer.

Peptide compounds useful in the invention may also be prepared using recombinant DNA techniques, using methods now known in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor (1989). Non-peptide compounds useful in the present invention may be prepared by art-known methods.

The compounds referenced above may form salts with various inorganic and organic acids and bases. Such salts include salts prepared with organic and inorganic acids, for example, HCl, HBr,  $H_2SO_4$ ,  $H_3PO_4$ , trifluoroacetic acid, acetic acid, formic acid, methanesulfonic acid, toluenesulfonic acid, maleic acid, fumaric acid succinic acid and tartaric acid and camphorsulfonic acid. Salts prepared with bases include ammonium salts, alkali metal salts, e.g., sodium and potassium salts, and alkali earth salts, e.g., calcium and magnesium salts. Acetate, hydrochloride, and trifluoroacetate salts are preferred. The salts may be formed by conventional means, as by reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a

solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.

#### Formulation and Administration

- 5           Compositions useful in the invention may conveniently be provided in the form of formulations suitable for parenteral (including intravenous, intramuscular and subcutaneous) or nasal or oral administration or suitably encapsulated or otherwise prepared by art-known methods for
- 10           oral administration. A suitable administration format may best be determined by a medical practitioner for each patient individually. Pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by
- 15           E.W. Martin. See also Wang, Y.J. and Hanson, M.A. "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers," Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S (1988).
- 20           Compounds useful in the invention can be provided as parenteral compositions for injection or infusion can, for example, be suspended in an inert oil, suitably a vegetable oil such as sesame, peanut, olive oil, or other acceptable carrier. Preferably, they are suspended in an aqueous
- 25           carrier, for example, in an isotonic buffer solution at a pH of about 5.6 to 7.4. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The compositions may contain pharmaceutically acceptable auxiliary substances as



required to approximate physiological conditions, such as pH buffering agents. Useful buffers include for example, sodium acetate/acetic acid buffers. A form of repository or "depot" slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection or delivery.

Preferably, these parenteral dosage forms are prepared according to the commonly owned patent application entitled, "Parenteral, Liquid Formulations for Amylin Agonist Peptides," Serial No. 60/035,140, filed January 8, 1997, which is incorporated herein by this reference, and include approximately 0.01 to 0.5% (w/v), respectively, of a compound in an aqueous system along with approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer to obtain a pH of the final composition of approximately 3.0 to 6.0 (more preferably 3.0 to 5.5), as well as approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonicifier in an aqueous continuous phase. Approximately 0.005 to 1.0% (w/v) of an antimicrobial preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol is also present in the preferred formulation of product designed to allow the patient to withdraw multiple doses. A sufficient amount of water for injection is used to obtain the desired concentration of solution. Sodium chloride, as well as other excipients, may also be present, if desired. Such excipients, however, must maintain the overall stability of the peptide. Most preferably, in the formulation for

parenteral administration, the polyhydric alcohol is mannitol, the buffer is an acetate buffer, the preservative is approximately 0.1 to 0.3 w/v% of m-cresol, and the pH is approximately 3.7 to 4.3.

- 5           The desired isotonicity may be accomplished using sodium chloride or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol, polyols (such as mannitol and sorbitol), or other inorganic or organic solutes. Sodium chloride is preferred
- 10 particularly for buffers containing sodium ions. If desired, solutions of the above compositions may be thickened with a thickening agent such as methyl cellulose. They may be prepared in emulsified form, either water in oil or oil in water. Any of a wide variety of
- 15 pharmaceutically acceptable emulsifying agents may be employed including, for example, acacia powder, a non-ionic surfactant (such as a Tween), or an ionic surfactant (such as alkali polyether alcohol sulfates or sulfonates, e.g., a Triton).
- 20           Compositions useful in the invention are prepared by mixing the ingredients following generally accepted procedures. For example, the selected components may be simply mixed in a blender or other standard device to produce a concentrated mixture which may then be adjusted
- 25 to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity.

For use by the physician, the compositions will be provided in dosage unit form containing an amount of a

30 compound of the present invention, for example, a compound

which will be effective in one or multiple doses to provide a therapeutic effect at the selected level.

Therapeutically effective amounts of a compound of the present invention for use in the control of hyperglycemia, including hyperglycemia associated with insulin resistance, are those that significantly lower post-prandial glucose levels with respect to control, as may be measured by comparing the area under the curve of postprandial glucose concentrations. As will be recognized by those in the field, an effective amount of therapeutic agent will vary with many factors including the age and weight of the patient, the patient's physical condition, the action to be obtained and other factors.

The effective single, divided or continuous doses of the compounds will typically be in the range of 1  $\mu\text{g/kg/day}$  to about 100  $\mu\text{g/kg/day}$ , preferably about 0.1  $\mu\text{g/kg/day}$  to about 10  $\mu\text{g/kg/day}$ , administered in a single dose or multiple doses.

As will be recognized by those in the field, an effective amount of therapeutic agent will vary with many factors including the age and weight of the patient, the patient's physical condition and other factors. Orally active compounds may be taken orally, however, dosages should be increased 5-10 fold, or should be increased (or decreased) in the ratio described earlier.

To assist in understanding the present invention, the following Examples are included which describe the results of several experiments. The experiments relating to this invention should not, of course, be construed as

specifically limiting the invention and such variations of

the invention, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the invention as described herein and hereinafter claimed.

5                    EXAMPLE 1

PREPARATION OF COMPOUND 1

Compound 1, having the following formula:

10                    Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-  
                      Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-  
                      Gly-Ser-Asn-Thr-Tyr        [SEQ.ID.NO. 1]

was assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc-aminomethyl)-phenoxy acetamidonorleucyl norleucine MBHA resin (Novabiochem, 0.44 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). Single-coupling  
15                    cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. The completed peptide resin was deprotected and cleaved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid  
20                    (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc.) The peptide was precipitated in ether/water (50 mL) and centrifuged. The precipitate was reconstituted in GAA and lyophilized. The lyophilized peptide was dissolved in water). Crude  
25                    purity was about 55%.

Used in purification steps were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).

The solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). The peptide had an observed retention time of 31 minutes. Purity of fractions was determined isocratically using a C-18 analytical column. Pure fractions were pooled furnishing the above-identified peptide. Yield was 84.2 mg (10.2% of theoretical). Analytical RP-HPLC (gradient 20% to 50% Solvent B in Solvent A over 20 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.5 minutes. Electrospray Mass Spectrometry (M): calculated 3308.7; found 3308.0.

#### EXAMPLE 2

##### PREPARATION OF COMPOUND 2

Compound 2, having the following formula:

4-methylpentanoyl-Ser-Thr-Ala-Val-Leu-Aib-Lys(For) -  
Leu-Ser-Gln-Glu-Leu-Aib-Lys(For) -Leu-Gln-Thr-Tyr-Pro-  
Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro [SEQ.ID.NO. 2]

was prepared in a similar way as that described in Example 1 except the N-terminal isocaproyl group was incorporated using isocaproic acid in the final synthesis cycle.

Preparative RP-HPLC was performed using a C-18 column (25% to 45% Solvent B in Solvent A over 40 minutes). The peptide had an observed retention time of 22 minutes.

Analytical RP-HPLC (30% to 50% Solvent B in Solvent A over 20 minutes) gave product peptide with a retention time of 18.7 minutes. Electrospray Mass Spectrometry [M+H]<sup>+</sup>:

34

calculated 3114.7; found 3114.7.

### EXAMPLE 3

#### PREPARATION OF COMPOUND 3

Compound 3, having the following formula:

5       Ac-Leu-Ser-Thr-Ser-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu  
          His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-  
          Asn-Thr-Tyr     [SEQ.ID.NO. 3]

was prepared in a similar way as that described in Example  
1. Acetylation was accomplished using acetic anhydride.

10       Preparative RP-HPLC was performed using a C-18 Supelco LC-  
          180B (21 X 250 mm) column with a flow rate of 200 mL/min  
          (25% to 45% Solvent B in Solvent A over 20 minutes) to give  
          peptide having an observed retention time of 17 minutes.  
          Analytical RP-HPLC (20% to 50% Solvent B in Solvent A over  
15       20 minutes) gave product peptide with a retention time of  
          16.7 minutes. FAB Mass Spectrometry [M+H]<sup>+</sup>: calculated  
          3277.6; found 3278.3.

### EXAMPLE 4

#### PREPARATION OF COMPOUND 4

20       Compound 4, having the following formula:

          Leu-Ser-Thr-Ala-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-  
          Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-  
          Gly-Ser-Asn-Thr-Tyr     [SEQ.ID.NO. 4]

was prepared in a similar way as that described in Example

35

1. Preparative RP-HPLC was performed using a C-18 column such as that described in Example 3 and eluting with a gradient (25% to 45% Solvent B in Solvent A over 20 minutes) to give peptide having an observed retention time of 13 minutes. Analytical RP-HPLC (20% to 50% Solvent B in Solvent A over 20 minutes) gave product peptide having a retention time of 15.05 minutes. Electrospray Mass Spectrometry (M): calculated 3276.7; found 3277.8.

#### EXAMPLE 5

##### PREPARATION OF COMPOUND 5

Compound 5, having the formula:

Leu-Ser-Thr-Ser-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-  
Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-  
Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 5]

was prepared in a similar way as that described in Example 1. Preparative RP-HPLC was performed using a C-18 column such as that described in Example 3 and eluting with a gradient (25% to 45% Solvent B in Solvent A over 20 minutes) to give peptide having an observed retention time of 14 minutes. Analytical RP-HPLC (20% to 50% Solvent B in Solvent A over 20 minutes) gave product peptide having a retention time of 15.5 minutes. Electrospray Mass Spectrometry (M): calculated 3292.7; found 3293.9.

#### EXAMPLE 6

##### PREPARATION OF COMPOUND 6

Compound 6 having the following formula:

36

Ac-Leu-Ser-Thr-Ala-Val-Leu-Gly-Arg-Leu-Ser-Gln-  
Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-  
Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 6]

was prepared in a similar way as that described in Example

1. Acetylation was accomplished using acetic anhydride.  
Preparative RP-HPLC was performed using a C-18 column as  
described in Example 1, eluting with a gradient (25% to 45%  
Solvent B in Solvent A over 20 minutes) to give peptide  
having an observed retention time of 17 minutes.

Analytical RP-HPLC (20% to 50% Solvent B in Solvent A over  
20 minutes) gave product peptide having a retention time of  
16.91 minutes. Electrospray Mass Spectrometry (M):  
calculated 3261.6; found 3262.5.

#### EXAMPLE 7

##### PREPARATION OF COMPOUND 7

Compound 7, having the following formula:

Ac-Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-Gln-  
Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-  
Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 7]

was prepared in a similar way as that described in Example

1. Acetylation was accomplished is acetic anhydride.

Preparative RP-HPLC was performed using a C-8 column as  
described in Example 1, eluting with a gradient (15% to 30%  
Solvent B in Solvent A over 40 minutes) to give peptide

having an observed retention time of 32 minutes.

Analytical RP-HPLC (20% to 50% Solvent B in Solvent A over



37

20 minutes) to give product peptide having a retention time of 16.83 minutes. Electrospray Mass Spectrometry (M): calculated 3350.8; found 3349.5.

EXAMPLE 8PREPARATION OF COMPOUND 8

Compound 8, having the following formula:

Val-Leu-Aib-Lys (For)-Leu-Ser-Gln-Gl-Leu-Aib-  
Lys (For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-  
Ser-Asn-Thr-Tyr [SEQ.ID.NO. 8]

was prepared in a way similar to that described in Example 1. Preparative RP-HPLC was performed using a C-8 column as described in Example 1, eluting with a gradient (25% to 50% Solvent B in Solvent A over 40 minutes) to give peptide having an observed retention time of 12 minutes.

Analytical RP-HPLC (20% to 40% Solvent B in Solvent A over 20 minutes) to give product peptide having a retention time of 19.17 minutes. Electrospray Mass Spectrometry (M): calculated 2879.5; found 2879.4.

EXAMPLE 9PREPARATION OF COMPOUND 9

Compound 9, having the following formula:

Ac-Val-Leu-Aib-Lys (For)-Leu-Ser-Gln-Glu-Leu-Aib-  
Lys (For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-  
Ser-Asn-Thr-Tyr [SEQ.ID.NO. 9]

was prepared in a way similar to that described in Example 1. Acetylation was accomplished using acetic anhydride. Preparative RP-HPLC was performed using a C-8 column as described in Example 1, eluting with a gradient (25% to 50% Solvent B in Solvent A over 40 minutes) to give peptide having an observed retention time of 13 minutes. Analytical RP-HPLC (20% to 50% Solvent B in Solvent A) was performed to give product peptide having a retention time of 14.24 minutes. Electrospray Mass Spectrometry (M): calculated 2921.5; found 2921.1.

#### EXAMPLE 10

##### PREPARATION OF COMPOUND 10

Compound 10, having the following formula:

4-methylpentanoyl-Ser-Thr-Ala-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 10]

is assembled on 4-(2'-4'-dimethoxyphenyl-Fmoc aminomethyl) phenoxyacetamido- norleucyl MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 1 except the N-terminal 4-methylpentanoyl group is incorporated using 4-methylpentanoic acid in the final synthesis cycle. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 20% to 50% Solvent B in Solvent A over 30 minutes) of the lyophilized

39

peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3237.43.

EXAMPLE 11PREPARATION OF COMPOUND 11

Compound 11, having the following formula:

4-methylpentanoyl-Ser-Thr-Cys-Val-Leu-Aib-  
Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-  
Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-  
Tyr [SEQ.ID.NO. 11]

is assembled on 4-(2'-4'-dimethoxyphenyl-Fmoc-aminomethyl) phenoxyacetamido- norleucyl MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 1 except the N-terminal 4-methylpentanoyl group is incorporated using 4-methylpentanoic acid in the final synthesis cycle. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 20% to 50% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3269.49.

EXAMPLE 12PREPARATION OF COMPOUND 12

Compound 12, having the following formula:

Ala-Thr-Aib-Lys(For)-Leu-Ala-Asn-Glu-Leu-Aib-  
Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-  
Ser-Asn-Thr-Tyr [SEQ.ID.NO. 12]

is assembled on 4-(2'-4'-dimethoxyphenyl-Fmoc aminomethyl)  
5 phenoxyacetamido- norleucyl MBHA resin (Novabiochem, 0.55  
mmole/g) using Fmoc-protected amino acids (Applied  
Biosystems, Inc.), cleaved from the resin, deprotected and  
purified in a similar way to Example 1. Used in analysis  
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA  
10 in ACN). Analytical RP-HPLC (gradient 20% to 50% Solvent B  
in Solvent A over 30 minutes) of the lyophilized peptide is  
then carried out to determine the retention time of the  
product peptide. Electrospray Mass Spectrometry (M):  
calculated 2809.89.

#### EXAMPLE 13

##### PREPARATION OF COMPOUND 13

Compound 13, having the following formula:

Ac-Ala-Thr-Aib-Lys(For)-Leu-Ala-Asn-Glu-Leu-Aib-  
Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-  
20 Ser-Asn-Thr-Tyr [SEQ.ID.NO. 13]

is assembled on 4-(2'-4'-dimethoxyphenyl-Fmoc-aminomethyl)  
phenoxyacetamido- norleucyl MBHA resin (Novabiochem, 0.55  
mmole/g) using Fmoc-protected amino acids (Applied  
Biosystems, Inc.), cleaved from the resin, deprotected and  
25 purified in a similar way to Example 1. Acetylation is  
accomplished using acetic anhydride. Used in analysis are

Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 20% to 50% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 2851.92.

#### EXAMPLE A

##### RECEPTOR BINDING ASSAYS

Receptor binding assays were performed using radiiodinated peptides and membranes from cells or tissues that contain relatively high densities of the receptor to be measured.

Binding of test compounds to amylin receptors was measured by the binding of  $^{125}\text{I}$ -BH-rat amylin ( $^{125}\text{I}$ -Bolton Hunter label on the N-terminal lysine) to membranes from rat nucleus accumbens as set forth below.

Binding of test compounds to CGRP receptors was measured by the binding of  $^{125}\text{I}$ -L- $\alpha$ CGRP ( $^{125}\text{I}$ -labeled at histidine) to membranes from human SK-N-MC neuroblastoma cells.

Binding of test compounds to calcitonin receptors was measured by the binding of  $^{125}\text{I}$ -human calcitonin ( $^{125}\text{I}$ -labeled at tyrosine) to membranes from human MCF7 breast carcinoma cells, which express high densities of adenylyl cyclase-coupled calcitonin receptors. A clonal sub-line (MCF7-7) which was isolated from the parental MCF7 cell line was used in these experiments.

Binding to Rat Nucleus Accumbens Membranes (Amylin

Receptors)

Evaluation of the binding of compounds to amylin receptors was carried out as follows.  $^{125}\text{I}$ -BH-rat amylin was purchased from Amersham Corporation (Arlington Heights, IL). Specific activities at time of use ranged from 1950 to 2000 Ci/mmol. Unlabeled peptides were obtained from BACHEM Inc. (Torrance, CA) and Peninsula Laboratories (Belmont, CA).

Male Sprague-Dawley rats (200 to 250 grams) were sacrificed by decapitation. Brains were removed to cold phosphate-buffered saline (PBS). From the ventral surface, cuts were made rostral to the hypothalamus, bounded laterally by the olfactory tracts and extending at a 45° angle medially from these tracts. This basal forebrain tissue, containing the nucleus accumbens and surrounding regions, was weighed and homogenized in ice-cold 20 mM HEPES buffer (20 mM HEPES acid, pH adjusted to 7.4 with NaOH at 23°C). Membranes were washed three times in fresh buffer by centrifugation for 15 minutes at 48,000 x g. The final membrane pellet was resuspended in 20 mM HEPES buffer containing 0.2 mM phenylmethylsulfonyl fluoride (PMSF).

To measure  $^{125}\text{I}$ -amylin binding, membranes from 4 mg original wet weight of tissue were incubated with  $^{125}\text{I}$ -amylin at 12 to 16 pM in 20 mM HEPES buffer containing 0.5 mg/ml bacitracin, 0.5 mg/ml bovine serum albumin, and 0.2 mM PMSF. Solutions were incubated for 60 minutes at 23°C. Incubations were terminated by filtration through GF/B glass fiber filters (Whatman Inc., Clifton, NJ) which had been presoaked for 4 hours in 0.3% polyethyleneimine in order to reduce nonspecific binding of radiolabeled

peptides. Filters were washed immediately before filtration with 5 ml cold PBS, and immediately after filtration with 15 ml cold PBS. Filters were removed and radioactivity assessed in a gamma-counter at a counting efficiency of 77%.

#### Binding to Membranes from SK-N-MC Cells (CGRP Receptors)

SK-N-MC cells (ATCC No. HTB-10) were homogenized in 50 mM Hepes buffer, pH 7.4, and membranes were collected by centrifugation for 15 min at 48000 x g. Membranes suspended at a concentration of 0.1 to 0.2 mg protein/0.2 ml aliquot were incubated in 50 mM Hepes, pH 7.4 containing bovine serum albumin, bacitracin, and 2mM MgCl<sub>2</sub> with 15 pM [<sup>125</sup>I]human-CGRP (labeled at <sup>10</sup>His, 2000 Ci/mmol) and unlabeled peptides. Additional methods were similar to those described for amylin receptor assays. K<sub>i</sub> was derived as IC<sub>50</sub>/(1+([L]/K<sub>d</sub>)) where [L] was 15 pM and K<sub>d</sub> was 3 pM.

SK-N-MC human neuroblastoma cells have been shown to contain a high-affinity CGRP receptor that is coupled adenylate cyclase and which has binding and specificity characteristics similar to CGRP receptors present in several other tissues (VanValen et al., 1990). K<sub>i</sub> values were derived from inhibition of [<sup>125</sup>I]hCGRP binding to membranes from SK-N-MC cells.

#### Binding to Membranes from T47D Cells (Calcitonin Receptors)

Membranes from human T47D breast carcinoma cells (ATCC No. HTB 133), previously shown to contain high densities of calcitonin receptors (Findlay et al., 1980). Membranes were prepared from confluent cultures of T47D cells as

described for SK-N-MC cells. Membranes were incubated with 32 pM [ $^{125}$ I]salmon calcitonin (labeled at  $^{22}$ Tyr, 2000 Ci/mmol), and with unlabeled peptides for 60 minutes at ambient temperature. Additional methods are similar to those described for CGRP receptor assays.  $K_i$  was derived as  $IC_{50}/(1+([L]/K_d))$  where [L] was 32 pM and  $K_d$  was 19 pM.

Binding to calcitonin receptors as quantified by displacement of [ $^{125}$ I]salmon calcitonin from membranes in human T47D carcinoma cells.

## 10 Results

Certain compounds of the present invention were tested in radioligand binding assays as described above to determine their affinities for amylin, calcitonin and CGRP receptors.

15 Competition curves were generated by measuring radioligand binding in the presence of increasing concentrations of test compounds with the half-maximal inhibitory concentration ( $IC_{50}$ ) determined using an iterative curve fitting program (nonlinear regression using 20 a 4-parameter logistic equation; Inplot program; Graph PAD Software, San Diego).



TABLE I

Competition for amylin,  
calcitonin, and CGRP receptors

5	Compound No.	Receptor IC <sub>50</sub> in nM [mean ± SEM (n)]		
		Amylin	Calcitonin	CGRP
	1	0.250±0.091 (4)	0.22±0.02 (3)	160±42 (4)
	2	12.0±1.3 (3)	0.37±0.03 (3)	>10,000 (1)
10	3	37.0±4.6 (2)	1.45±0.04 (2)	>10,000 (2)
	4	0.066±0.008 (3)	0.13±0.07 (2)	92±13 (2)
	5	0.092±0.011 (2)	0.15±0.05 (2)	44±12 (2)
	6	18.6±5.3 (4)	0.56±0.02 (2)	>10,000 (2)
	7	0.16±0.11 (2)	0.21±0.07 (2)	1,400 (1)
15	8	23.6 (1)	93 (1)	>10,000 (1)
	9	7.6 (1)	24 (1)	>10,000 (1)

All test compounds demonstrated relative affinities for amylin (nucleus accumbens) and calcitonin (T47D) receptors, compared with their affinities for CGRP (SK-N-MC) receptors. For example, the test compounds showed at least a 300-fold lower affinity for the CGRP receptors than the amylin receptors. Within the series of compounds, Compounds 1, 4, 5, 7, 8 and 9 showed similar potencies of amylin and calcitonin receptors. Compounds 2, 3 and 6 showed greater affinity for calcitonin receptors than for amylin receptors.

EXAMPLE BASSAY OF ADENYL CYCLASE STIMULATION

Compounds of the present invention were assayed for functional activity at calcitonin receptors using human T47D (ATCC No. HTB 133) and MCF7 (ATCC No. 22) breast carcinoma cells, both of which contain calcitonin receptors coupled to the stimulation of adenylyl cyclase activity. For Compound 1, functional activity at rat calcitonin C1a receptors was also determined in HEK293 cells (ATCC No. CRL 1573) which had undergone stable transfection with the rat calcitonin C1a receptor.

Cells were grown to confluency in 96 well plates. Medium was removed (by shaking into sink and tapping plate onto tissue). Medium was replaced with 100  $\mu$ L dPBS (10 mL of 10X Dulbecco's PBS up to 100 mL with water; and 0.1 g FA-free BSA and 0.1 g glucose; pH adjusted to 7.4) containing 0.1% BSA and 0.1% glucose. Cells were incubated in an air incubator for 20 to 30 minutes at 37°C. Medium was replaced with fresh dPBS containing 0.5 mM IBMX (4.5 mg IBMX was added into 50 mL modified dPBS; mixture was sonicated until IBMX was in solution). Cells were incubated 10 minutes. Hormone and/or test compound was diluted into dPBS medium containing IBMX. A 100  $\mu$ L aliquot of hormone (or test compound) solution was added to plates. Cells were incubated for 20 to 30 minutes at 37°C in a humidified air incubator. The reaction was stopped by addition of 20  $\mu$ L of 5% TCA. Plates containing cells were kept at 4°C for 15 minutes. A 20  $\mu$ L aliquot of 0.8 M Trizma was added to neutralize media. Plates were

agitated, then spun at 2000 rpm in a floor centrifuge. Supernatant was decanted and directly used in acetate buffer in a standard cAMP radioimmunoassay.

In breast carcinoma cells, human calcitonin stimulated increases in cyclic AMP accumulation with an  $EC_{50}$  of 0.45 nM (MCF7-7) and 3.1 nM (T47D). Human amylin was 5-fold (MCF7-7) to 7-fold (T47D) less potent than calcitonin in stimulating adenyl cyclase activity in these cells. Figure 1 depicts the effect of Compound 1 on cyclic AMP production in T47D cells. Compound 1 strongly stimulated cyclic AMP accumulation in T47D cells, with an  $EC_{50}$  of 2.2 nM as shown in Figure 1. In these cells, Compound 1 was somewhat more potent than human calcitonin in stimulating adenyl cyclase activity. Thus, Compound 1 are functional agonists at calcitonin receptors in human cells. Compound 1 was also tested in cells expressing rat calcitonin  $Cl\alpha$  receptors, and again strongly stimulated adenyl cyclase activity, with an  $EC_{50}$ =0.97 nM (data not shown).

Compound 2 was also tested for functional activity at calcitonin receptors. Compound 2 had partial agonist activity in MCF7-7 cells, producing an increase in cyclic AMP that was approximately 20% of the increase production by human calcitonin. Compound 2 had an  $EC_{50}$  of 1.6 nM (3.5-fold less potent than human calcitonin) in producing this effect.

Compound 4 ( $EC_{50}$ =3.5 nM) and Compound 6 ( $EC_{50}$ =34 nM) were also tested in this assay and were observed to stimulate adenyl cyclase activity in MCF7-7 cells, with 7-fold and 80-fold lower potency than human calcitonin.

EXAMPLE CSOLEUS MUSCLE ASSAY

Determination of amylin antagonist activity of test compounds in the soleus muscle assay was carried out as follows. Male Harlan Sprague-Dawley rats of approximately 200 g mass were used in order to maintain mass of the split soleus muscle less than 40 mg. The animals were fasted for 4 hours prior to sacrifice by decapitation. The skin was stripped from the lower limb which was then pinned out on corkboard. The *tendo achilles* was cut just above *os calcis* and *m. gastrocnemius* reflected out from the posterior aspect of the tibia. *M. soleus*, a small 15-20 mm long, 0.5 mm thick flat muscle on the bone surface of *m. gastrocnemius* was then stripped clear and the perimysium cleaned off using fine scissors and forceps. *M. soleus* was then split into equal parts using a blade passed antero-posteriorly through the belly of the muscle to obtain a total of 4 muscle strips from each animal. After dissecting the muscle from the animal, it was kept for a short period in physiological saline. It was not necessary that the muscle be held under tension as this had no demonstrable effects on radioglucose incorporation into glycogen.

Muscles were added to 50 mL Erlenmeyer flasks containing 10 mL of a pregassed Krebs-Ringer bicarbonate buffer containing (each liter) NaCl 118.5 mmol (6.93 g), KCl 5.94 mmol (443 mg), CaCl<sub>2</sub> 2.54 mmol (282 mg), MgSO<sub>4</sub> 1.19 mmol (143 mg), KH<sub>2</sub>PO<sub>4</sub> 1.19 mmol (162 mg), NaHCO<sub>3</sub> 25 mmol (2.1 g), 5.5mmol glucose (1 g) and recombinant human insulin (Humulin-R, Eli Lilly, IN) and

the test compound, as detailed below. The pH at 37°C was verified as being between 7.1 and 7.4. Muscles were assigned to different flasks so that the 4 muscle pieces from each animal were evenly distributed among the 5 different assay conditions. The incubation media were gassed by gently blowing carbogen (95% O<sub>2</sub>, 5% CO<sub>2</sub>) over the surface while being continuously agitated at 37°C in an oscillating water bath. After a half-hour "preincubation" period, 0.5 µCi of U-<sup>14</sup>C-glucose was added to each flask 10 which was incubated for a further 60 minutes. Each muscle piece was then rapidly removed, blotted and frozen in liquid N<sub>2</sub>, weighed and stored for subsequent determination of <sup>14</sup>C-glycogen.

<sup>14</sup>C-glycogen determination was performed in a 7 mL 15 scintillation vial. Each frozen muscle specimen was placed in a vial and digested in 1 mL 60% potassium hydroxide at 70°C for 45 minutes under continuous agitation. Dissolved glycogen was precipitated out onto the vial by the addition of 3 mL absolute ethanol and overnight cooling at -20°C.

20 The supernatant was gently aspirated, the glycogen washed again with ethanol, aspirated and the precipitate dried under vacuum. All ethanol is evaporated to avoid quenching during scintillation counting. The remaining glycogen was redissolved in 1 mL water and 4 mL scintillation fluid and 25 counted for <sup>14</sup>C.

The rate of glucose incorporation into glycogen (expressed in µmol/g/hr) was obtained from the specific activity of <sup>14</sup>C-glucose in the 5.5 mM glucose of the incubation medium, and the total <sup>14</sup>C counts remaining in 30 the glycogen extracted from each muscle. Dose/response

curves were fitted to a 4-parameter logistic model using a least-squares iterative routine (ALLFIT, v2.7, NIH, MD) to derive  $EC_{50}$ s. Because  $EC_{50}$  is log-normally distributed, it is expressed  $\pm$  standard error of the logarithm. Pairwise comparisons were performed using t-test based routines of SYSTAT (Wilkinson, "SYSTAT: the system for statistics," SYSTAT Inc., Evanston IL (1989)).

Dose response curves were generated with muscles added to media containing 7.1 nM (1000  $\mu$ U/mL) insulin and each test compound added at final (nominal) concentrations of 0, 1, 3, 10, 30, 100, 300 and 1000 nM. Each assay also contained internal positive controls consisting of a single batch of archived rat amylin, lyophilized and stored at  $-70^{\circ}\text{C}$ .

$EC_{50}$  measurements of amylin preparations in the soleus muscle assay range typically from about 1 to 10 nM, although some commercial preparations which are less than 90% pure have higher  $EC_{50}$ s presumably due to the presence of contaminants that result in a lower measured activity. Results for test compounds are set forth below and in Figures 2 and 3.

In the isolated, incubated, rat soleus muscle preparation, Compound 1 and Compound 2 exhibited no discernable amylin agonist activity in inhibition of incorporation of glucose into glycogen. In this assay insulin increases the incorporation of  $^{14}\text{C}$ , derived from  $^{14}\text{C}$ -labeled glucose in the incubation medium, into glycogen by a factor of 3-4 over a period of 1 hour. The glycogen is subsequently extracted from incubated soleus muscle strips and analyzed. In this assay, amylin action is

typified by a reduction in incorporation of the  $^{14}\text{C}$  from glucose into glycogen (shown herein Figure 2 in the presence of insulin). The antagonism of amylin action is thus indicated by the prevention of the amylin-mediated reduction of incorporation of  $^{14}\text{C}$  into glycogen.

Results of experiments with Compound 1 and Compound 2 are shown in Figures 2A and 2B. Figures 2A depicts results with Compound 1 and Figure 2B depicts results with Compound 2. The second bar in each figure shows the stimulatory effect of insulin (1000  $\mu\text{Units/ml}$ , 7.1 nM) on  $^{14}\text{C}$  incorporation from  $^{14}\text{C}$ -glucose. The third bar in each figure shows the effect of amylin (100 nM) in reducing the insulin-stimulated  $^{14}\text{C}$  incorporation from  $^{14}\text{C}$ -glucose to values near to those observed in the absence of insulin. The fourth bar in each figure shows that neither Compound 1 (100 nM) nor Compound 2 (100 nM) affected the response to insulin. That is, neither Compound 1 nor Compound 2 displayed amylin agonist activity in this assay. In the fifth set of bars, the effect of amylin (100 nM) on insulin-stimulated incorporation of glucose into glycogen (7.1 nM) (as shown in the third set of bars) is reversed by the addition of either Compound 1 (1  $\mu\text{M}$ ) or Compound 2 (1  $\mu\text{M}$ ). That is, Compound 1 and Compound 2 displayed amylin antagonist activity in this assay.

Figure 3 depicts a dose response curve for the reversal by Compound 1 of the effects of rat amylin (100 nM) on insulin-stimulated incorporation of  $^{14}\text{C}$  into glycogen from  $^{14}\text{C}$ -glucose in isolated soleus muscle. The  $\text{IC}_{50}$  value from the graph is about 4 nM for Compound 1.

EXAMPLE DEFFECT ON PLASMA GLUCOSE, LACTATE AND CALCIUM LEVELS

Male Harlan Sprague Dawley rats were housed at 22.7°±0.8° C. in a 12:12 hour light: dark cycle

- 5 (experiments being performed during the light cycle) and fed and watered ad libitum (Diest LM-485, Teklad, Madison, Wis.). Animals used were aged 87-94 days and weighed 353-392 g. They were deprived of food for -20 hours prior to experimentation.

- 10 Anesthesia was induced with 5% halothane, maintained at 2% during surgery and at 0.8-1% during recordings. Tracheotomy and cannulation of the right femoral artery and saphenous vein were performed. The femoral arterial line was connected to a pressure transducer (Spectramed P23XL
- 15 transducer, Model 13-4615-58 amplifier, Gould, Cleveland, Ohio) and perfused with heparinized saline (2U.mL) at 3.0 mL/hr. Colonic temperature was measured using a thermistor probe and controller (Model 73A, YSI, Yellow Springs, Ohio) which provided closed-loop control of core temperature by
- 20 switching a heated operating table. The signal for mean arterial pressure was periodically sampled and stored with 12-bit precision at 1 Hz using a computerized data acquisition system (DT2801A A.D converters, Data Translation, Marlboro, Mass.; AST Premium 386 computer, AST
- 25 Research, Irvine, calif.; Labtech Notebook software, Laboratory Technologies Corp, Wilmington, Mass.).

Synthetic rat amylin (Bachem, Torrance, Calif.) was tested for its ability to bind in the amylin receptor assay, and for bioactivity using the soleus muscle assay.

- 30 The test compounds were made by solid phase peptide



synthesis as described above.

The following treatment groups were utilized: (1) control rats (n=5) which, at t=0, were injected subcutaneously with 0.1 mL of 0.15M saline; (2) amylin injection rats (n=5) which at t=0, were administered 100  $\mu$ g synthetic rat amylin in 0.1 mL saline as a subcutaneous bolus into the ventral abdominal wall; and (3) amylin injection following test compound preinfusion rats (n=1). In group 3, subcutaneous amylin injection (as in Group 2) was preceded by a primed/continuous intravenous infusion of test compounds. A bolus intravenous dose of 0.5 mg of test compound at -30 min was followed by a 1 mg/hr intravenous infusion of test compound until t=120 min.

Arterial samples of 250  $\mu$ L were drawn into non-heparinized Natelson tubes at -30, -15, 0, 15, 30, 45, 60, 90 and 120 minutes (relative to amylin injection), transferred to chilled EDTA microphage tubes, spun, and the separated plasma analyzed immediately for glucose and lactate using immobilized enzyme chemistries (glucose oxidase, L-lactate oxidase, Analyzer model 2300-STAT, YSI, Yellow Springs, Ohio).

Total plasma calcium was measured using a dye-binding assay (o-cresolphthalein complexone, Sigma procedure 587; Sigma, St. Louis, MO, USA).

The response to subcutaneous injections of 100  $\mu$ g of Compound 1 or Compound 2 were compared to those obtained with either 100  $\mu$ g of rat amylin or a saline vehicle control. Plasma glucose and lactate concentrations typically have been observed to increase following rat amylin injections. This response to amylin has been

interpreted as being at least partly due to amylin-mediated glycogenolysis, release of lactate from muscle and subsequent gluconeogenesis from the released lactate. In addition, plasma calcium levels are typically observed to fall; this effect may be due to amylin action at calcitonin receptors.

Figures 4A to 4C depict the response of plasma glucose (Figure 4A), lactate (Figure 4B) and calcium (Figure 4C) levels in anesthetized rats following subcutaneous injection of Compound 1 compared to such levels following injection of rat amylin or a saline vehicle control. Figures 5A to 5C show the response of plasma glucose (Figure 5A), lactate (Figure 5B) and calcium Figure 5C) levels in anaesthetized rats following injection of Compound 2 compared to such levels following injection of rat amylin or saline vehicle control.

As depicted in Figures 4A to 4C and 5A to 5C, neither Compound 1 nor Compound 2 increased either plasma lactate or plasma glucose, a result consistent with their lack of amylin agonism observed in the soleus muscle assay (see Example C). Compounds 1 and 2 caused a fall in plasma calcium concentration, which was consistent with their activities as a calcitonin agonists.

#### EXAMPLE E

##### EFFECT ON PLASMA GLUCOSE, LACTATE AND CALCIUM LEVELS, IN THE PRESENCE OF AMYLIN

Male Harlan Sprague Dawley rats (age 75 to 85 days, mass 300-350 g) fasted 18 to 20 hours were halothane anesthetized and cannulated via the saphenous vein for

infusions/injections and via the femoral artery for sampling of glucose/lactate/calcium and for recording arterial pressure. Heart rate was also monitored via ECG.

One and a half hours after surgery the rats were infused with a 1.5 mg bolus of Compound 2 followed by an infusion of 3 mg/hour for an additional 1.5 hours ( $t=0.5$  to 1.0 hour). At  $t=0$  hours (0.5 hours after the start of the primed/continuous test compound infusion) a 50  $\mu\text{g}$  bolus of rat amylin was administered followed by an infusion of 50  $\mu\text{g}/\text{hour}$  of rat amylin which continued until the end of the experiment. Blood samples were collected every 10 minutes for the first 2 hours of the test and then every 30 minutes. Mean arterial pressure and heart rate were continuously recorded from  $t=0.5$  to  $t=+0.5$  hours. The study was terminated at  $t=6$  hours. A previously reported amylin antagonist, AC253 (Prickett, K.S. et al., "Design of Receptor Selection Peptides that Antagonize the Actions of Amylin In Vivo", *Peptides Chemistry Structure and Biology* (Kaumaya and Hodges, eds.), pages 620 to 622 (1996), was included as a positive control.

Figures 6A to 6D depict the effects of Compound 1 and Compound 2 on plasma glucose (Figure 6A), plasma lactate (Figure 6B), plasma calcium (Figure 6C) and mean arterial pressure (Figure 6D) as a function of time after amylin administration. In this protocol, rat amylin antagonist activity is indicated by the suppression of the increases in plasma glucose and lactate which typically follow amylin administration. Preinfusions with Compound 1 or Compound 2 resulted in smaller increases in lactate and glucose levels than those observed in control rats preinfused with

saline alone, which indicates that these compounds antagonized the hyperlacemic and hyperglycemic actions of amylin *in vivo*. A fall in plasma calcium levels began after infusion of Compound 1 or Compound 2 and was not changed by the subsequent amylin infusion. This observed effect on plasma calcium is considered typical of amylin and calcitonin agonist activity. The lack of ability of these compounds to reverse the blood pressure lowering effect of amylin, an effect known to be mediated through CGRP receptors, demonstrates the selective activity of the test compounds.

#### EXAMPLE F

##### PHENOL RED GASTRIC EMPTYING ASSAY

Gastric emptying was measured using a modification (Plourde *et al.*, Life Sci. 53:857-862 (1993)) of the original method of Scarpignato *et al.* (Arch. Int. Pharmacodyn. Ther. 246:286-295 (1980)). Conscious rats received by gavage. 1.5 mL of an a caloric gel containing 1.5% methyl cellulose (M-0262, Sigma Chemical Co., St. Louis, MO) and 0.05% phenol red indicator. Twenty minutes after gavage, rats were anesthetized using 5% halothane, the stomach exposed and clamped at the pyloric and lower esophageal sphincters using artery forceps, removed and opened into an alkaline solution which was made up to a fixed volume. Stomach content was derived from the intensity of the phenol red in the alkaline solution, measured by absorbance at a wavelength of 560 nm. In most experiments, the stomach was clear. In other experiments, particulate gastric contents were centrifuged to clear the

solution for absorbance measurements. Where the diluted gastric contents remained turbid, the spectroscopic absorbance due to phenol red was derived as the difference between that present in alkaline versus acidified diluent.

5 In separate experiments on 7 rats, the stomach and small intestine were both excised and opened into an alkaline solution. The quantity of phenol red that could be recovered from the upper gastrointestinal tract within 29 minutes of gavage was  $89 \pm 4\%$ ; dye which appeared to bind irrecoverably to the gut luminal surface may have accounted for the balance. To compensate for this small loss, percent of stomach contents remaining after 20 minutes were expressed as a fraction of the gastric contents recovered from control rats sacrificed immediately after gavage in the same experiment. Percent gastric emptying contents remaining = (absorbance at 20 min)/(absorbance at 0 min). Dose response curves for gastric emptying were fitted to a 4-parameter logistic model using a least-squares iterative routine (ALLFIT, v2.7, NIH, Bethesda, MD) to derive  $ED_{50}$ s.

10 Because  $ED_{50}$  is log-normally distributed, it is expressed  $\pm$  standard error of the logarithm. Pairwise comparisons were performed using one-way analysis of variance and the Student-Newman-Keuls multiple comparisons test (Instat v2.0, GraphPad Software, San Diego, CA) using  $P < 0.05$  as the level of significance.

In dose response studies, rat amylin (Bachem, Torrance, CA) dissolved in 0.15M saline, was administered as a 0.1 mL subcutaneous bolus in doses of 0, 0.01, 0.1, 1, 10 or 100  $\mu$ g 5 minutes before gavage in Harlan Sprague Dawley (non-diabetic) rats fasted 20 hours and diabetic BB

rats fasted 6 hours. When subcutaneous amylin injections were given 5 minutes before gavage with phenol red indicator, there was a dose-dependent suppression of gastric emptying (data not shown). Suppression of gastric emptying was complete in normal HSD rats administered 1  $\mu$ g of amylin, and in diabetic rats administered 10  $\mu$ g ( $P = 0.22, 0.14$ ). The  $ED_{50}$  for inhibition of gastric emptying in normal rats was 0.43  $\mu$ g (0.60 nmol/kg)  $\pm$  0.19 log units, and was 2.2  $\mu$ g (2.3 nmol/kg)  $\pm$  0.18 log units in diabetic rats.

Amylin (rat or human) and compounds that exhibit amylin-like actions in isolated soleus muscle (including, salmon calcitonin, CGRP, and rat calcitonin) have been observed to dose-dependently inhibit gastric emptying in the present conscious rat model. Adrenomedullin, which has been observed to behave as a CGRP agonist but not as an amylin or calcitonin agonist, does not inhibit gastric emptying at the highest doses (100  $\mu$ g) used in this model (indicating that inhibition of gastric emptying in this model is unlikely to be mediated by CGRP receptors).

As shown Figure 7, amylin and rat calcitonin had similar potencies in inhibiting gastric emptying ( $ED_{50}$ s of 0.21 and 0.41  $\mu$ g/rat, respectively; n.s.). Salmon calcitonin was more potent than rat calcitonin in its gastric emptying inhibition effect ( $ED_{50}$  0.12  $\mu$ g/rat;  $P < 0.03$ ). Both Compound 1 and Compound 2 behaved as potent amylin and calcitonin agonists in inhibition of gastric emptying.

We claim:

1. A compound of the formula:

$X_1-X_2-X_3$ -Leu- $X_4$ -Glu-Leu- $X_5$ - $X_6$ -Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn- $X_7$ - $Z_1$  [SEQ.ID.NO.27] wherein:

- 5 (a)  $X_1$  is (i) a group of two amino acid residues selected from the group consisting of Leu-Leu, Val-Leu, Ile-Leu, tert-Leu-Leu, Nle-Leu, and Ala-Thr, and N-acylated derivatives thereof; or (ii) the group  $Z_1$ -Ser-Thr- $Z_2$ -Val-Leu [SEQ.ID.NO. 28] wherein  $Z_1$  is an amino acid residue selected from the group consisting of Leu, Val, Ile, tert-Leu, Nva, Abu, and Nle or an N-acylated derivative thereof or  $Z_1$  is an alkanoyl group; and
- 10  $Z_2$  is a amino acid residue selected from the group consisting of Ala, Ser, Cys, and Thr;
- 15 (b)  $X_2$  is an amino acid residue selected from the group consisting of Gly, Glu, Asn or Aib;
- (c)  $X_3$  is an amino acid residue selected from the group consisting of Arg, Orn, Lys and  $\epsilon$ -amidated derivatives thereof;
- 20 (d)  $X_4$  is a group of two amino acid residues selected from the group consisting of Ser-Gln, Thr-Gln, Ala-Asn and Thr-Asn;
- (e)  $X_5$  is an amino acid residue selected from the group consisting of His, Aib, Ile, Leu and Val;
- 25 (f)  $X_6$  is an amino acid residue selected from the group consisting of Arg, Orn and Lys and  $\epsilon$ -amidated derivatives thereof;
- (g)  $X_7$  is a group having 6 amino acid residues selected

from the group consisting of

- (i) Thr-Gly-Ser-Asn-Thr-Tyr-NH<sub>2</sub> [SEQ.ID.NO. 29];
  - (ii) Thr-Gly-Ser-Gly-Thr-Pro-NH<sub>2</sub> [SEQ.ID.NO. 30];
  - (iii) Val-Gly-Ser-Asn-Thr-Tyr-NH<sub>2</sub> [SEQ.ID.NO. 31];
  - (iv) Val-Gly-Ser-Gly-Thr-Pro-NH<sub>2</sub> [SEQ.ID.NO. 32]; and
- (h) Z<sub>3</sub> is OH or NH<sub>2</sub>;

with the proviso that the compound does not have the formula of any of SEQ. ID. NOS. 14 to 26; and pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 wherein Z<sub>3</sub> is NH<sub>2</sub>.

3. A compound according to claim 1 wherein X<sub>2</sub> is Gly.

4. A compound according to claim 3 wherein X<sub>5</sub> is His or Aib.

5. A compound according to claim 4 wherein X<sub>4</sub> is Ser-Glu.

6. A compound according to claim 5 wherein X<sub>1</sub> is Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 29] or Thr-Gly-Ser-Gly-Thr-Pro-NH<sub>2</sub> [SEQ.ID.NO. 30].

7. A compound according to claim 6 wherein X<sub>1</sub> is Z<sub>1</sub>-Ser-Thr-Z<sub>2</sub>-Val-Leu [SEQ.ID.NO.28].

8. A compound according to claim 7 wherein X<sub>3</sub> and X<sub>6</sub>



are e-amidated with a carboxylic acid having 1 to 8 carbon atoms.

9. A compound according to claim 9 wherein  $Z_1$  is an alkanoyl group having 1 to about 10 carbon atoms or Leu.

10. A compound according to claim 9 wherein  $Z_2$  is Ala or Cys.

11. A compound according to claim 10 wherein  $Z_1$  is an alkanoyl group.

12. A compound according to claim 11 wherein  $X_3$  and  $X_6$  are formamidated or acetamidated.

13. A compound according to claim 12 wherein  $Z_2$  is Ala.

14. A compound according to claim 13 wherein  $X_3$  and  $X_6$  are Lys(For).

15. A compound according to claim 14 wherein  $Z_1$  is 4-methylpentanoyl.

16. A compound according to claim 1 which has an amino acid sequence selected from the group consisting of:

Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-  
Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-  
Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 1];

62

4-methylpentanoyl-Ser-Thr-Ala-Val-Leu-Aib-  
Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-  
Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-  
Pro [SEQ.ID.NO. 2];

5 Ac-Leu-Ser-Thr-Ser-Val-Leu-Gly-Arg-Leu-Ser-Gln-  
Glu-Leu His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-  
Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 3];

Leu-Ser-Thr-Ala-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-  
Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-  
Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 4];

Leu-Ser-Thr-Ser-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-  
Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-  
Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 5];

15 Ac-Leu-Ser-Thr-Ala-Val-Leu-Gly-Arg-Leu-Ser-Gln-  
Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-  
Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 6];

Ac-Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-Gln-  
Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-  
Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 7];

20 Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Gl-Leu-Aib-  
Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-  
Ser-Asn-Thr-Tyr [SEQ.ID.NO. 8];

Ac-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-

Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 9];

4-methylpentanoyl-Ser-Thr-Ala-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 10];

4-methylpentanoyl-Ser-Thr-Cys-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 11];

Ala-Thr-Aib-Lys(For)-Leu-Ala-Asn-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 12]; and

Ac-Ala-Thr-Aib-Lys(For)-Leu-Ala-Asn-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 13].

17. The compound Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 1].

18. The compound 4-methylpentanoyl-Ser-Thr-Ala-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro [SEQ.ID.NO. 2].

19. A composition comprising a compound of any of claims 1 to 18 in a pharmaceutically acceptable carrier.

20. A method of treating diabetes in a subject in need of treatment which comprises administering to said subject a therapeutically effective amount of a compound of any of claims 1, 2, 15, 16, 17 or 18.

21. A method according to claim 20 wherein said diabetes is type I diabetes.

22. A method according to claim 20 wherein said diabetes is type II diabetes.

23. A method of beneficially regulating gastrointestinal motility in a subject comprising administering to said subject a therapeutically effective amount of a compound of any of claims 1, 2, 15, 16, 17 or 18.


24. A method according to claim 23 wherein said beneficial regulation of gastrointestinal motility comprises delaying gastric emptying.

25. A method of treating a disorder selected from the group consisting of: impaired glucose tolerance; postprandial hyperglycemia; obesity; and Syndrome x; in a subject in need of treatment which comprises

65

administering to said subject a therapeutically effective amount of a compound of any of claims 1, 2, 15, 16, 17 or 18.

Figure 1



2/17

09/622104




Figure 2A

3/17

09/622104




Figure 2B



09/622104




Figure 3

09/622104




FIGURE 4A

6/17

09/622104

## Compound 1, Effects on lactate




FIGURE 4B

09/622104




FIGURE 4C

8/17

09/622104

## Compound 2, Effects on glucose




FIGURE 5A

9/17

09/622104

## Compound 2, Effects on lactate




FIGURE 5B

10/17

09/622104

## Compound 2, Effects on calcium




FIGURE 5C

11/17

09/622104

# Antagonism of Rat Amylin Effects on Glucose




FIGURE 6A



12/17

## Antagonism of Rat Amylin Effects on Lactate




FIGURE 6B

13/17

09/622104

## Antagonism of Rat Amylin Effects on Calcium




FIGURE 6C

14/17

09/622104




FIGURE 6D




FIGURE 7

09/622104

FIGURE 8

Compounds of the formula:  $X_1-X_2-X_3$ -Leu-Glu-Leu- $X_4$ - $X_5$ -Leu-Glu-Thr-Tyr-Pro-Arg-Thr-Asn- $X_6$ -NH<sub>2</sub>

Comp. No.	Compounds of the formula: $X_1-X_2-X_3$ -Leu-Gln-Thr- $X_4-X_5$ -Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn- $X_6$ -NH <sub>2</sub>											$X_7$							
	$X_1$	$X_2$	$X_3$	$X_4$	$X_5$	Leu	Gln	Leu	His	Arg	Leu	Gln	Tyr	Pro	Arg	Thr	Asn	$X_8$	NH <sub>2</sub>
1	Leu	Ser	Thr	Cys	Val	Leu	Gly	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)
2	4-methylpentanoyl	Ser	Thr	Ala	Val	Leu	Gly	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)
3	Ac	Leu	Ser	Thr	Ser	Val	Leu	Gly	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb
4	Leu	Ser	Thr	Ala	Val	Leu	Gly	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)
5	Leu	Ser	Thr	Ser	Val	Leu	Gly	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)
6	Ac	Leu	Ser	Thr	Ala	Val	Leu	Gly	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb
7	Ac	Leu	Ser	Thr	Cys	Val	Leu	Gly	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb
8	Val	Leu	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb
9	Ac-Val	Leu	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb
10	4-methylpentanoyl	Ser	Thr	Ala	Val	Leu	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb
11	4-methylpentanoyl	Ser	Thr	Cys	Val	Leu	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb
12	Ala	Thr	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb
13	(Ac)	Ala	Thr	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)	Alb	Lys (For)

09/622104

FIGURE 9  
Compounds of the formula:  $X_1-X_2-X_3$ -Leu-Glu-Leu- $X_4$ - $X_5$ -Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn- $X_6$ -NH<sub>2</sub>

SEQ. ID. NO.	$X_1$			$X_2$	$X_3$	Leu	$X_4$	Gln Leu	$X_5$	Leu Gln Thr Tyr Pro Arg Thr Asn	$X_6$	Met
14	Leu Ser Thr Cys Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	His	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Gly Thr Pro	Met	
15	Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	His	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Gly Thr Pro	Met	
16	Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	His	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Asn Thr Tyr	Met	
17	(AcNH) Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	His	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Asn Thr Tyr	Met	
18	Ac- Leu Ser Thr Ala Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	His	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Gly Thr Pro	Met	
19	Ac- Leu Ser Thr Ala Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	Alb	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Gly Thr Pro	Met	
20	Isooctoyl- Ser Thr Ala Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	His	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Gly Thr Pro	Met	
21	H Leu Ser Thr Ala Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	His	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Gly Thr Pro	Met	
22	Adamantacetyl- Ser Thr Ala Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	His	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Gly Thr Pro	Met	
23	CH <sub>3</sub> CO Ser Thr Ala Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	His	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Gly Thr Pro	Met	
24	Cyclohexylacetonyl- Ser Thr Ala Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	His	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Gly Thr Pro	Met	
25	Cyclopentyl C(O)- Ser Thr Ala Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	His	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Gly Thr Pro	Met	
26	Decanoyl- Ser Thr Ala Val Leu	Gly	Lys	Leu	Ser Gln	Gln Leu	His	Lys	Leu Gln Thr Tyr Pro Arg Thr Asn	Thr Gly Ser Gly Thr Pro	Met	

JUL 16 2001

Lyon & Lyon LLP  
Docket Information  
256/153**DECLARATION  
Utility Application**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **NOVEL MIXED AMYLIN ACTIVITY COMPOUNDS** the specification of which

(Check One)

☐

is attached hereto OR

☒

on August 10, 2000 entry into the U.S. National Phase was requested and received U.S. Application Number 09/622,104 based upon PCT International Application No. PCT/US99/02603.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed	
			Yes	No
PCT/US99/02603	WO	5 February 1999	X	

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date
60/074,746	13 February 1998

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned
N/A	PCT/US99/02603	5 February 1999	N/A

**RECEIVED**

JUL 17 2001

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

201	FULL NAME OF INVENTOR	FIRST Name Nigel	MIDDLE Initial R. A.	LAST Name Beeley	
	RESIDENCE & CITIZENSHIP	City Solana Beach	State or Foreign Country California		Country of Citizenship USA
	POST OFFICE ADDRESS	227 Loma Corte Dr.	City Solana Beach	State or Country CA	Zip Code 92075
INVENTOR'S SIGNATURE _____				DATE _____	

202	FULL NAME OF INVENTOR	FIRST Name Kathryn	MIDDLE Initial	LAST Name Prickett	
	RESIDENCE & CITIZENSHIP	City San Diego	State or Foreign Country California		Country of Citizenship USA
	POST OFFICE ADDRESS	7612 Trailbrush Terr.	City San Diego	State or Country CA	Zip Code 92126
INVENTOR'S SIGNATURE _____				DATE _____	

203	FULL NAME OF INVENTOR	FIRST Name Kevin	MIDDLE Initial	LAST Name Beaumont	
	RESIDENCE & CITIZENSHIP	City San Diego	State or Foreign Country California		Country of Citizenship USA
	POST OFFICE ADDRESS	10872 Pinot Noir Circle	City San Diego	State or Country CA	Zip Code 92131
INVENTOR'S SIGNATURE <i>Kevin Beaumont</i>				DATE <i>9/27/00</i>	



JUL 16 2001

Lyon & Lyon LLP  
Docket Information  
256/153**DECLARATION  
Utility Application**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **NOVEL MIXED AMYLIN ACTIVITY COMPOUNDS** the specification of which

(Check One)



is attached hereto OR



on August 10, 2000 entry into the U.S. National Phase was requested and received U.S. Application Number 09/622,104 based upon PCT International Application No. PCT/US99/02603.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed	
			Yes	No
PCT/US99/02603	WO	5 February 1999	X	

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date
60/074,746	13 February 1998

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned
N/A	PCT/US99/02603	5 February 1999	N/A

RECEIVED

JUL 17 2001

OFFICE OF PETITIONS

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

201	FULL NAME OF INVENTOR	FIRST Name Nigel	MIDDLE Initial R. A.	LAST Name Beeley	
	RESIDENCE & CITIZENSHIP	City Solana Beach	State or Foreign Country California		Country of Citizenship <del>USA</del> UK <i>FR</i>
	POST OFFICE ADDRESS	227 Loma Corte Dr.	City Solana Beach	State or Country CA	Zip Code 92075
INVENTOR'S SIGNATURE <i>Nigel Beeley</i>				DATE <i>9/22/2000</i>	

202	FULL NAME OF INVENTOR	FIRST Name Kathryn	MIDDLE Initial	LAST Name Prickett	
	RESIDENCE & CITIZENSHIP	City San Diego	State or Foreign Country California		Country of Citizenship USA
	POST OFFICE ADDRESS	7612 Trailbrush Terr.	City San Diego	State or Country CA	Zip Code 92126
INVENTOR'S SIGNATURE _____				DATE _____	

203	FULL NAME OF INVENTOR	FIRST Name Kevin	MIDDLE Initial	LAST Name Beaumont	
	RESIDENCE & CITIZENSHIP	City San Diego	State or Foreign Country California		Country of Citizenship USA
	POST OFFICE ADDRESS	10872 Pinot Noir Circle	City San Diego	State or Country CA	Zip Code 92131
INVENTOR'S SIGNATURE _____				DATE _____	

RECEIVED

JUL 17 2001

OFFICE OF PETITIONS



#7

**DECLARATION  
Utility Application**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **NOVEL MIXED AMYLIN ACTIVITY COMPOUNDS** the specification of which

(Check One)

☐

is attached hereto OR

☒

on August 10, 2000 entry into the U.S. National Phase was requested and received U.S. Application Number 09/622,104 based upon PCT International Application No. PCT/US99/02603.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed	
			Yes	No
PCT/US99/02603	WO	5 February 1999	X	

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date
60/074,746	13 February 1998

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned
N/A	PCT/US99/02603	5 February 1999	N/A

**RECEIVED**

**JUL 17 2001**

**OFFICE OF PETITIONS**

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1-00

201	FULL NAME OF INVENTOR	FIRST Name <u>Nigel</u>	MIDDLE Initial <u>R. A.</u>	LAST Name <u>Beeley</u>	
	RESIDENCE & CITIZENSHIP	City <u>Solana Beach</u>	State or Foreign Country <u>California</u> <b>CA</b>		Country of Citizenship <u>USA</u>
	POST OFFICE ADDRESS	<u>227 Loma Corte Dr.</u>		City <u>Solana Beach</u>	State or Country <u>CA</u> Zip Code <u>92075</u>
INVENTOR'S SIGNATURE _____					DATE _____

2-00

202	FULL NAME OF INVENTOR	FIRST Name <u>Kathryn</u>	MIDDLE Initial	LAST Name <u>Prickett</u>	
	RESIDENCE & CITIZENSHIP	City <u>San Diego</u>	State or Foreign Country <u>California</u> <b>CA</b>		Country of Citizenship <u>USA</u>
	POST OFFICE ADDRESS	<u>7612 Trailbrush Terr.</u>		City <u>San Diego</u>	State or Country <u>CA</u> Zip Code <u>92126</u>
INVENTOR'S SIGNATURE <u>Kathryn A. Prickett</u>					DATE <u>9/24/00</u>

3-00

203	FULL NAME OF INVENTOR	FIRST Name <u>Kevin</u>	MIDDLE Initial	LAST Name <u>Beaumont</u>	
	RESIDENCE & CITIZENSHIP	City <u>San Diego</u>	State or Foreign Country <u>California</u> <b>CA</b>		Country of Citizenship <u>USA</u>
	POST OFFICE ADDRESS	<u>10872 Pinot Noir Circle</u>		City <u>San Diego</u>	State or Country <u>CA</u> Zip Code <u>92131</u>
INVENTOR'S SIGNATURE _____					DATE _____

RECEIVED

JUL 17 2001

OFFICE OF PETITIONS